<?xml version="1.0" encoding="utf-8"?>
<uniprot xmlns="http://uniprot.org/uniprot" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://uniprot.org/uniprot http://www.uniprot.org/support/docs/uniprot.xsd">
<entry dataset="Swiss-Prot" created="1986-07-21" modified="2020-10-07" version="253">
<accession>P02649</accession>
<accession>B2RC15</accession>
<accession>C0JYY5</accession>
<accession>Q9P2S4</accession>
<name>APOE_HUMAN</name>
<protein>
<recommendedName>
<fullName>Apolipoprotein E</fullName>
<shortName>Apo-E</shortName>
</recommendedName>
</protein>
<gene>
<name type="primary">APOE</name>
</gene>
<organism>
<name type="scientific">Homo sapiens</name>
<name type="common">Human</name>
<dbReference type="NCBI Taxonomy" id="9606"/>
<lineage>
<taxon>Eukaryota</taxon>
<taxon>Metazoa</taxon>
<taxon>Chordata</taxon>
<taxon>Craniata</taxon>
<taxon>Vertebrata</taxon>
<taxon>Euteleostomi</taxon>
<taxon>Mammalia</taxon>
<taxon>Eutheria</taxon>
<taxon>Euarchontoglires</taxon>
<taxon>Primates</taxon>
<taxon>Haplorrhini</taxon>
<taxon>Catarrhini</taxon>
<taxon>Hominidae</taxon>
<taxon>Homo</taxon>
</lineage>
</organism>
<reference key="1">
<citation type="journal article" date="1984" name="J. Biol. Chem." volume="259" first="5495" last="5499">
<title>Synthesis, intracellular processing, and signal peptide of human apolipoprotein E.</title>
<authorList>
<person name="Zannis V.I."/>
<person name="McPherson J."/>
<person name="Goldberger G."/>
<person name="Karathanasis S.K."/>
<person name="Breslow J.L."/>
</authorList>
<dbReference type="PubMed" id="6325438"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] (ALLELE APOE*3)</scope>
</reference>
<reference key="2">
<citation type="journal article" date="1984" name="J. Biol. Chem." volume="259" first="6498" last="6504">
<title>Human apolipoprotein E mRNA. cDNA cloning and nucleotide sequencing of a new variant.</title>
<authorList>
<person name="McLean J.W."/>
<person name="Elshourbagy N.A."/>
<person name="Chang D.J."/>
<person name="Mahley R.W."/>
<person name="Taylor J.M."/>
</authorList>
<dbReference type="PubMed" id="6327682"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA]</scope>
<scope>VARIANTS THR-117 AND PRO-170</scope>
</reference>
<reference key="3">
<citation type="journal article" date="1985" name="Proc. Natl. Acad. Sci. U.S.A." volume="82" first="3445" last="3449">
<title>Nucleotide sequence and structure of the human apolipoprotein E gene.</title>
<authorList>
<person name="Paik Y.-K."/>
<person name="Chang D.J."/>
<person name="Reardon C.A."/>
<person name="Davies G.E."/>
<person name="Mahley R.W."/>
<person name="Taylor J.M."/>
</authorList>
<dbReference type="PubMed" id="2987927"/>
<dbReference type="DOI" id="10.1073/pnas.82.10.3445"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*4)</scope>
<scope>VARIANT AD2 ARG-130</scope>
</reference>
<reference key="4">
<citation type="journal article" date="1988" name="Genomics" volume="3" first="373" last="379">
<title>Genotyping and sequence analysis of apolipoprotein E isoforms.</title>
<authorList>
<person name="Emi M."/>
<person name="Wu L.L."/>
<person name="Robertson M.A."/>
<person name="Myers R.L."/>
<person name="Hegele R.A."/>
<person name="Williams R.R."/>
<person name="White R."/>
<person name="Lalouel J.-M."/>
</authorList>
<dbReference type="PubMed" id="3243553"/>
<dbReference type="DOI" id="10.1016/0888-7543(88)90130-9"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*2)</scope>
<scope>VARIANT CYS-176</scope>
</reference>
<reference key="5">
<citation type="journal article" date="1998" name="DNA Seq." volume="9" first="89" last="100">
<title>Sequencing of 42kb of the APO E-C2 gene cluster reveals a new gene: PEREC1.</title>
<authorList>
<person name="Freitas E.M."/>
<person name="Zhang W.J."/>
<person name="Lalonde J.P."/>
<person name="Tay G.K."/>
<person name="Gaudieri S."/>
<person name="Ashworth L.K."/>
<person name="Van Bockxmeer F.M."/>
<person name="Dawkins R.L."/>
</authorList>
<dbReference type="PubMed" id="10520737"/>
<dbReference type="DOI" id="10.3109/10425179809086433"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3)</scope>
</reference>
<reference key="6">
<citation type="journal article" date="2000" name="Genome Res." volume="10" first="1532" last="1545">
<title>Sequence diversity and large-scale typing of SNPs in the human apolipoprotein E gene.</title>
<authorList>
<person name="Nickerson D.A."/>
<person name="Taylor S.L."/>
<person name="Fullerton S.M."/>
<person name="Weiss K.M."/>
<person name="Clark A.G."/>
<person name="Stengard J.H."/>
<person name="Salomaa V."/>
<person name="Boerwinkle E."/>
<person name="Sing C.F."/>
</authorList>
<dbReference type="PubMed" id="11042151"/>
<dbReference type="DOI" id="10.1101/gr.146900"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3)</scope>
<scope>VARIANTS PRO-46; ARG-130; CYS-163 AND CYS-176</scope>
</reference>
<reference key="7">
<citation type="journal article" date="2004" name="Nat. Genet." volume="36" first="40" last="45">
<title>Complete sequencing and characterization of 21,243 full-length human cDNAs.</title>
<authorList>
<person name="Ota T."/>
<person name="Suzuki Y."/>
<person name="Nishikawa T."/>
<person name="Otsuki T."/>
<person name="Sugiyama T."/>
<person name="Irie R."/>
<person name="Wakamatsu A."/>
<person name="Hayashi K."/>
<person name="Sato H."/>
<person name="Nagai K."/>
<person name="Kimura K."/>
<person name="Makita H."/>
<person name="Sekine M."/>
<person name="Obayashi M."/>
<person name="Nishi T."/>
<person name="Shibahara T."/>
<person name="Tanaka T."/>
<person name="Ishii S."/>
<person name="Yamamoto J."/>
<person name="Saito K."/>
<person name="Kawai Y."/>
<person name="Isono Y."/>
<person name="Nakamura Y."/>
<person name="Nagahari K."/>
<person name="Murakami K."/>
<person name="Yasuda T."/>
<person name="Iwayanagi T."/>
<person name="Wagatsuma M."/>
<person name="Shiratori A."/>
<person name="Sudo H."/>
<person name="Hosoiri T."/>
<person name="Kaku Y."/>
<person name="Kodaira H."/>
<person name="Kondo H."/>
<person name="Sugawara M."/>
<person name="Takahashi M."/>
<person name="Kanda K."/>
<person name="Yokoi T."/>
<person name="Furuya T."/>
<person name="Kikkawa E."/>
<person name="Omura Y."/>
<person name="Abe K."/>
<person name="Kamihara K."/>
<person name="Katsuta N."/>
<person name="Sato K."/>
<person name="Tanikawa M."/>
<person name="Yamazaki M."/>
<person name="Ninomiya K."/>
<person name="Ishibashi T."/>
<person name="Yamashita H."/>
<person name="Murakawa K."/>
<person name="Fujimori K."/>
<person name="Tanai H."/>
<person name="Kimata M."/>
<person name="Watanabe M."/>
<person name="Hiraoka S."/>
<person name="Chiba Y."/>
<person name="Ishida S."/>
<person name="Ono Y."/>
<person name="Takiguchi S."/>
<person name="Watanabe S."/>
<person name="Yosida M."/>
<person name="Hotuta T."/>
<person name="Kusano J."/>
<person name="Kanehori K."/>
<person name="Takahashi-Fujii A."/>
<person name="Hara H."/>
<person name="Tanase T.-O."/>
<person name="Nomura Y."/>
<person name="Togiya S."/>
<person name="Komai F."/>
<person name="Hara R."/>
<person name="Takeuchi K."/>
<person name="Arita M."/>
<person name="Imose N."/>
<person name="Musashino K."/>
<person name="Yuuki H."/>
<person name="Oshima A."/>
<person name="Sasaki N."/>
<person name="Aotsuka S."/>
<person name="Yoshikawa Y."/>
<person name="Matsunawa H."/>
<person name="Ichihara T."/>
<person name="Shiohata N."/>
<person name="Sano S."/>
<person name="Moriya S."/>
<person name="Momiyama H."/>
<person name="Satoh N."/>
<person name="Takami S."/>
<person name="Terashima Y."/>
<person name="Suzuki O."/>
<person name="Nakagawa S."/>
<person name="Senoh A."/>
<person name="Mizoguchi H."/>
<person name="Goto Y."/>
<person name="Shimizu F."/>
<person name="Wakebe H."/>
<person name="Hishigaki H."/>
<person name="Watanabe T."/>
<person name="Sugiyama A."/>
<person name="Takemoto M."/>
<person name="Kawakami B."/>
<person name="Yamazaki M."/>
<person name="Watanabe K."/>
<person name="Kumagai A."/>
<person name="Itakura S."/>
<person name="Fukuzumi Y."/>
<person name="Fujimori Y."/>
<person name="Komiyama M."/>
<person name="Tashiro H."/>
<person name="Tanigami A."/>
<person name="Fujiwara T."/>
<person name="Ono T."/>
<person name="Yamada K."/>
<person name="Fujii Y."/>
<person name="Ozaki K."/>
<person name="Hirao M."/>
<person name="Ohmori Y."/>
<person name="Kawabata A."/>
<person name="Hikiji T."/>
<person name="Kobatake N."/>
<person name="Inagaki H."/>
<person name="Ikema Y."/>
<person name="Okamoto S."/>
<person name="Okitani R."/>
<person name="Kawakami T."/>
<person name="Noguchi S."/>
<person name="Itoh T."/>
<person name="Shigeta K."/>
<person name="Senba T."/>
<person name="Matsumura K."/>
<person name="Nakajima Y."/>
<person name="Mizuno T."/>
<person name="Morinaga M."/>
<person name="Sasaki M."/>
<person name="Togashi T."/>
<person name="Oyama M."/>
<person name="Hata H."/>
<person name="Watanabe M."/>
<person name="Komatsu T."/>
<person name="Mizushima-Sugano J."/>
<person name="Satoh T."/>
<person name="Shirai Y."/>
<person name="Takahashi Y."/>
<person name="Nakagawa K."/>
<person name="Okumura K."/>
<person name="Nagase T."/>
<person name="Nomura N."/>
<person name="Kikuchi H."/>
<person name="Masuho Y."/>
<person name="Yamashita R."/>
<person name="Nakai K."/>
<person name="Yada T."/>
<person name="Nakamura Y."/>
<person name="Ohara O."/>
<person name="Isogai T."/>
<person name="Sugano S."/>
</authorList>
<dbReference type="PubMed" id="14702039"/>
<dbReference type="DOI" id="10.1038/ng1285"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE APOE*3)</scope>
<source>
<tissue>Cerebellum</tissue>
</source>
</reference>
<reference key="8">
<citation type="submission" date="2008-12" db="EMBL/GenBank/DDBJ databases">
<authorList>
<consortium name="NHLBI resequencing and genotyping service (RS&amp;G)"/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ALLELE APOE*3)</scope>
</reference>
<reference key="9">
<citation type="journal article" date="2004" name="Genome Res." volume="14" first="2121" last="2127">
<title>The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).</title>
<authorList>
<consortium name="The MGC Project Team"/>
</authorList>
<dbReference type="PubMed" id="15489334"/>
<dbReference type="DOI" id="10.1101/gr.2596504"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ALLELE APOE*3)</scope>
<source>
<tissue>Eye</tissue>
</source>
</reference>
<reference key="10">
<citation type="submission" date="1999-11" db="EMBL/GenBank/DDBJ databases">
<title>A new apolipoprotein E variant (Gln46--&gt;His).</title>
<authorList>
<person name="Imura T."/>
<person name="Kimura H."/>
<person name="Kawasaki M."/>
</authorList>
</citation>
<scope>NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 16-78</scope>
<scope>VARIANT HIS-64</scope>
<source>
<tissue>Blood</tissue>
</source>
</reference>
<reference key="11">
<citation type="journal article" date="1982" name="J. Biol. Chem." volume="257" first="14639" last="14641">
<title>Identification and DNA sequence of a human apolipoprotein E cDNA clone.</title>
<authorList>
<person name="Breslow J.L."/>
<person name="McPherson J."/>
<person name="Nussbaum A.L."/>
<person name="Williams H.W."/>
<person name="Lofquist-Kahl F."/>
<person name="Karathanasis S.K."/>
<person name="Zannis V.I."/>
</authorList>
<dbReference type="PubMed" id="6897404"/>
</citation>
<scope>NUCLEOTIDE SEQUENCE [MRNA] OF 99-317 (ALLELE APOE*3)</scope>
</reference>
<reference key="12">
<citation type="journal article" date="1983" name="J. Biol. Chem." volume="258" first="11422" last="11422">
<authorList>
<person name="Breslow J.L."/>
<person name="McPherson J."/>
<person name="Nussbaum A.L."/>
<person name="Williams H.W."/>
<person name="Lofquist-Kahl F."/>
<person name="Karathanasis S.K."/>
<person name="Zannis V.I."/>
</authorList>
</citation>
<scope>ERRATUM OF PUBMED:6897404</scope>
</reference>
<reference key="13">
<citation type="journal article" date="1982" name="J. Biol. Chem." volume="257" first="4171" last="4178">
<title>Human apolipoprotein E. The complete amino acid sequence.</title>
<authorList>
<person name="Rall S.C. Jr."/>
<person name="Weisgraber K.H."/>
<person name="Mahley R.W."/>
</authorList>
<dbReference type="PubMed" id="7068630"/>
</citation>
<scope>PROTEIN SEQUENCE OF 19-317 (ALLELE APOE*2)</scope>
</reference>
<reference key="14">
<citation type="journal article" date="1983" name="Biochim. Biophys. Acta" volume="750" first="411" last="417">
<title>Cholesteryl ester and apolipoprotein E transfer between human high density lipoproteins and chylomicrons.</title>
<authorList>
<person name="Marcel Y.L."/>
<person name="Vezina C."/>
<person name="Milne R.W."/>
</authorList>
<dbReference type="PubMed" id="6860692"/>
<dbReference type="DOI" id="10.1016/0005-2760(83)90047-4"/>
</citation>
<scope>FUNCTION IN LIPOPROTEINS CONVERSION</scope>
</reference>
<reference key="15">
<citation type="journal article" date="1986" name="Biochem. Biophys. Res. Commun." volume="134" first="783" last="789">
<title>Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains.</title>
<authorList>
<person name="Cardin A.D."/>
<person name="Hirose N."/>
<person name="Blankenship D.T."/>
<person name="Jackson R.L."/>
<person name="Harmony J.A.K."/>
<person name="Sparrow D.A."/>
<person name="Sparrow J.T."/>
</authorList>
<dbReference type="PubMed" id="3947350"/>
<dbReference type="DOI" id="10.1016/s0006-291x(86)80489-2"/>
</citation>
<scope>HEPARIN-BINDING SITES</scope>
</reference>
<reference key="16">
<citation type="journal article" date="1987" name="J. Biol. Chem." volume="262" first="14352" last="14360">
<title>Lipoproteins and their receptors in the central nervous system. Characterization of the lipoproteins in cerebrospinal fluid and identification of apolipoprotein B,E(LDL) receptors in the brain.</title>
<authorList>
<person name="Pitas R.E."/>
<person name="Boyles J.K."/>
<person name="Lee S.H."/>
<person name="Hui D."/>
<person name="Weisgraber K.H."/>
</authorList>
<dbReference type="PubMed" id="3115992"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="17">
<citation type="journal article" date="2019" name="Clin. Chim. Acta" volume="489" first="29" last="34">
<title>Soluble LR11 competes with amyloid beta in binding to cerebrospinal fluid-high-density lipoprotein.</title>
<authorList>
<person name="Yano K."/>
<person name="Hirayama S."/>
<person name="Misawa N."/>
<person name="Furuta A."/>
<person name="Ueno T."/>
<person name="Motoi Y."/>
<person name="Seino U."/>
<person name="Ebinuma H."/>
<person name="Ikeuchi T."/>
<person name="Schneider W.J."/>
<person name="Bujo H."/>
<person name="Miida T."/>
</authorList>
<dbReference type="PubMed" id="30448281"/>
<dbReference type="DOI" id="10.1016/j.cca.2018.11.024"/>
</citation>
<scope>INTERACTION WITH SORL1</scope>
</reference>
<reference key="18">
<citation type="journal article" date="1988" name="J. Biol. Chem." volume="263" first="3542" last="3545">
<title>Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions.</title>
<authorList>
<person name="Lalazar A."/>
<person name="Weisgraber K.H."/>
<person name="Rall S.C. Jr."/>
<person name="Giladi H."/>
<person name="Innerarity T.L."/>
<person name="Levanon A.Z."/>
<person name="Boyles J.K."/>
<person name="Amit B."/>
<person name="Gorecki M."/>
<person name="Mahley R.W."/>
</authorList>
<dbReference type="PubMed" id="2831187"/>
</citation>
<scope>CHARACTERIZATION OF VARIANTS SER-154 AND PRO-170</scope>
<scope>MUTAGENESIS OF SER-157; HIS-158; LYS-161; LEU-162; LEU-167 AND ARG-168</scope>
</reference>
<reference key="19">
<citation type="journal article" date="1989" name="J. Biol. Chem." volume="264" first="9094" last="9101">
<title>Glycosylation of human apolipoprotein E. The carbohydrate attachment site is threonine 194.</title>
<authorList>
<person name="Wernette-Hammond M.E."/>
<person name="Lauer S.J."/>
<person name="Corsini A."/>
<person name="Walker D."/>
<person name="Taylor J.M."/>
<person name="Rall S.C. Jr."/>
</authorList>
<dbReference type="PubMed" id="2498325"/>
</citation>
<scope>SUBCELLULAR LOCATION</scope>
<scope>GLYCOSYLATION AT THR-212</scope>
<scope>MUTAGENESIS OF THR-212</scope>
</reference>
<reference key="20">
<citation type="journal article" date="1989" name="Proc. Natl. Acad. Sci. U.S.A." volume="86" first="5810" last="5814">
<title>Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins.</title>
<authorList>
<person name="Kowal R.C."/>
<person name="Herz J."/>
<person name="Goldstein J.L."/>
<person name="Esser V."/>
<person name="Brown M.S."/>
</authorList>
<dbReference type="PubMed" id="2762297"/>
<dbReference type="DOI" id="10.1073/pnas.86.15.5810"/>
</citation>
<scope>FUNCTION IN VLDL CLEARANCE</scope>
</reference>
<reference key="21">
<citation type="journal article" date="1990" name="J. Lipid Res." volume="31" first="1503" last="1511">
<title>Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine-arginine interchange at residue 112.</title>
<authorList>
<person name="Weisgraber K.H."/>
</authorList>
<dbReference type="PubMed" id="2280190"/>
</citation>
<scope>REGION</scope>
<scope>CHARACTERIZATION OF VARIANT ARG-130 AND ARG-176</scope>
</reference>
<reference key="22">
<citation type="journal article" date="1991" name="Biochim. Biophys. Acta" volume="1085" first="336" last="342">
<title>Effects of exogenous apo E-3 and of cholesterol-enriched meals on the cellular metabolism of human chylomicrons and their remnants.</title>
<authorList>
<person name="Arnon R."/>
<person name="Sehayek E."/>
<person name="Vogel T."/>
<person name="Eisenberg S."/>
</authorList>
<dbReference type="PubMed" id="1911868"/>
<dbReference type="DOI" id="10.1016/0005-2760(91)90138-8"/>
</citation>
<scope>FUNCTION IN CHYLOMICRONS CLEARANCE</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="23">
<citation type="journal article" date="1991" name="J. Biol. Chem." volume="266" first="18259" last="18267">
<title>Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway.</title>
<authorList>
<person name="Sehayek E."/>
<person name="Eisenberg S."/>
</authorList>
<dbReference type="PubMed" id="1917954"/>
</citation>
<scope>FUNCTION IN VLDL AND IDL CLEARANCE</scope>
</reference>
<reference key="24">
<citation type="journal article" date="1993" name="J. Biol. Chem." volume="268" first="15745" last="15750">
<title>Discrete carboxyl-terminal segments of apolipoprotein E mediate lipoprotein association and protein oligomerization.</title>
<authorList>
<person name="Westerlund J.A."/>
<person name="Weisgraber K.H."/>
</authorList>
<dbReference type="PubMed" id="8340399"/>
</citation>
<scope>SUBUNIT</scope>
<scope>SUBCELLULAR LOCATION</scope>
<scope>REGION</scope>
</reference>
<reference key="25">
<citation type="journal article" date="1993" name="Proc. Natl. Acad. Sci. U.S.A." volume="90" first="8098" last="8102">
<title>Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease.</title>
<authorList>
<person name="Strittmatter W.J."/>
<person name="Weisgraber K.H."/>
<person name="Huang D.Y."/>
<person name="Dong L.M."/>
<person name="Salvesen G.S."/>
<person name="Pericak-Vance M."/>
<person name="Schmechel D."/>
<person name="Saunders A.M."/>
<person name="Goldgaber D."/>
<person name="Roses A.D."/>
</authorList>
<dbReference type="PubMed" id="8367470"/>
<dbReference type="DOI" id="10.1073/pnas.90.17.8098"/>
</citation>
<scope>INTERACTION WITH APP/A4 AMYLOID-BETA PEPTIDE</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="26">
<citation type="journal article" date="1994" name="Neurosci. Lett." volume="182" first="55" last="58">
<title>Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAP2c: implications for Alzheimer's disease.</title>
<authorList>
<person name="Huang D.Y."/>
<person name="Goedert M."/>
<person name="Jakes R."/>
<person name="Weisgraber K.H."/>
<person name="Garner C.C."/>
<person name="Saunders A.M."/>
<person name="Pericak-Vance M.A."/>
<person name="Schmechel D.E."/>
<person name="Roses A.D."/>
<person name="Strittmatter W.J."/>
</authorList>
<dbReference type="PubMed" id="7891887"/>
<dbReference type="DOI" id="10.1016/0304-3940(94)90204-6"/>
</citation>
<scope>INTERACTION WITH MAP2</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="27">
<citation type="journal article" date="1994" name="Proc. Natl. Acad. Sci. U.S.A." volume="91" first="11183" last="11186">
<title>Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: implications for Alzheimer disease.</title>
<authorList>
<person name="Strittmatter W.J."/>
<person name="Saunders A.M."/>
<person name="Goedert M."/>
<person name="Weisgraber K.H."/>
<person name="Dong L.M."/>
<person name="Jakes R."/>
<person name="Huang D.Y."/>
<person name="Pericak-Vance M."/>
<person name="Schmechel D."/>
<person name="Roses A.D."/>
</authorList>
<dbReference type="PubMed" id="7972031"/>
<dbReference type="DOI" id="10.1073/pnas.91.23.11183"/>
</citation>
<scope>INTERACTION WITH MAPT</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="28">
<citation type="journal article" date="1995" name="J. Biol. Chem." volume="270" first="13070" last="13075">
<title>Identification of glycoprotein 330 as an endocytic receptor for apolipoprotein J/clusterin.</title>
<authorList>
<person name="Kounnas M.Z."/>
<person name="Loukinova E.B."/>
<person name="Stefansson S."/>
<person name="Harmony J.A.K."/>
<person name="Brewer B.H."/>
<person name="Strickland D.K."/>
<person name="Argraves W.S."/>
</authorList>
<dbReference type="PubMed" id="7768901"/>
<dbReference type="DOI" id="10.1074/jbc.270.22.13070"/>
</citation>
<scope>FUNCTION</scope>
<scope>LRP2-BINDING</scope>
</reference>
<reference key="29">
<citation type="journal article" date="1996" name="J. Biol. Chem." volume="271" first="30121" last="30125">
<title>Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein.</title>
<authorList>
<person name="Fagan A.M."/>
<person name="Bu G."/>
<person name="Sun Y."/>
<person name="Daugherty A."/>
<person name="Holtzman D.M."/>
</authorList>
<dbReference type="PubMed" id="8939961"/>
<dbReference type="DOI" id="10.1074/jbc.271.47.30121"/>
</citation>
<scope>FUNCTION IN NEURITE OUTGROWTH</scope>
<scope>LRP-BINDING</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="30">
<citation type="journal article" date="1997" name="J. Biol. Chem." volume="272" first="31285" last="31292">
<title>Heparan sulfate proteoglycans participate in hepatic lipase and apolipoprotein E-mediated binding and uptake of plasma lipoproteins, including high density lipoproteins.</title>
<authorList>
<person name="Ji Z.S."/>
<person name="Dichek H.L."/>
<person name="Miranda R.D."/>
<person name="Mahley R.W."/>
</authorList>
<dbReference type="PubMed" id="9395455"/>
<dbReference type="DOI" id="10.1074/jbc.272.50.31285"/>
</citation>
<scope>FUNCTION IN HDL CLEARANCE</scope>
<scope>HEPARAN SULFATE-BINDING</scope>
</reference>
<reference key="31">
<citation type="journal article" date="1998" name="J. Biol. Chem." volume="273" first="5645" last="5654">
<title>The HepG2 extracellular matrix contains separate heparinase- and lipid-releasable pools of ApoE. Implications for hepatic lipoprotein metabolism.</title>
<authorList>
<person name="Burgess J.W."/>
<person name="Gould D.R."/>
<person name="Marcel Y.L."/>
</authorList>
<dbReference type="PubMed" id="9488694"/>
<dbReference type="DOI" id="10.1074/jbc.273.10.5645"/>
</citation>
<scope>FUNCTION</scope>
<scope>HEPARAN-SULFATE-BINDING</scope>
<scope>SUBCELLULAR LOCATION</scope>
</reference>
<reference key="32">
<citation type="journal article" date="1999" name="Am. J. Pathol." volume="154" first="601" last="611">
<title>Specific regional transcription of apolipoprotein E in human brain neurons.</title>
<authorList>
<person name="Xu P.T."/>
<person name="Gilbert J.R."/>
<person name="Qiu H.L."/>
<person name="Ervin J."/>
<person name="Rothrock-Christian T.R."/>
<person name="Hulette C."/>
<person name="Schmechel D.E."/>
</authorList>
<dbReference type="PubMed" id="10027417"/>
<dbReference type="DOI" id="10.1016/s0002-9440(10)65305-9"/>
</citation>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="33">
<citation type="journal article" date="1999" name="Biochim. Biophys. Acta" volume="1454" first="296" last="308">
<title>Glycation of apolipoprotein E impairs its binding to heparin: identification of the major glycation site.</title>
<authorList>
<person name="Shuvaev V.V."/>
<person name="Fujii J."/>
<person name="Kawasaki Y."/>
<person name="Itoh H."/>
<person name="Hamaoka R."/>
<person name="Barbier A."/>
<person name="Ziegler O."/>
<person name="Siest G."/>
<person name="Taniguchi N."/>
</authorList>
<dbReference type="PubMed" id="10452964"/>
<dbReference type="DOI" id="10.1016/s0925-4439(99)00047-2"/>
</citation>
<scope>GLYCATION AT LYS-93</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="34">
<citation type="journal article" date="2001" name="Proc. Natl. Acad. Sci. U.S.A." volume="98" first="8838" last="8843">
<title>Apolipoprotein E fragments present in Alzheimer's disease brains induce neurofibrillary tangle-like intracellular inclusions in neurons.</title>
<authorList>
<person name="Huang Y."/>
<person name="Liu X.Q."/>
<person name="Wyss-Coray T."/>
<person name="Brecht W.J."/>
<person name="Sanan D.A."/>
<person name="Mahley R.W."/>
</authorList>
<dbReference type="PubMed" id="11447277"/>
<dbReference type="DOI" id="10.1073/pnas.151254698"/>
</citation>
<scope>PTM</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="35">
<citation type="journal article" date="2003" name="Biochemistry" volume="42" first="10406" last="10417">
<title>Domains of apoE required for binding to apoE receptor 2 and to phospholipids: implications for the functions of apoE in the brain.</title>
<authorList>
<person name="Li X."/>
<person name="Kypreos K."/>
<person name="Zanni E.E."/>
<person name="Zannis V."/>
</authorList>
<dbReference type="PubMed" id="12950167"/>
<dbReference type="DOI" id="10.1021/bi027093c"/>
</citation>
<scope>FUNCTION</scope>
<scope>LRP8-BINDING</scope>
<scope>CHARACTERIZATION OF VARIANT CYS-176</scope>
</reference>
<reference key="36">
<citation type="journal article" date="2004" name="J. Lipid Res." volume="45" first="839" last="848">
<title>Molecular interactions between apoE and ABCA1: impact on apoE lipidation.</title>
<authorList>
<person name="Krimbou L."/>
<person name="Denis M."/>
<person name="Haidar B."/>
<person name="Carrier M."/>
<person name="Marcil M."/>
<person name="Genest J. Jr."/>
</authorList>
<dbReference type="PubMed" id="14754908"/>
<dbReference type="DOI" id="10.1194/jlr.m300418-jlr200"/>
</citation>
<scope>FUNCTION IN REVERSE CHOLESTEROL TRANSPORT</scope>
<scope>INTERACTION WITH ABCA1</scope>
</reference>
<reference key="37">
<citation type="journal article" date="2009" name="Nat. Methods" volume="6" first="809" last="811">
<title>Enrichment of glycopeptides for glycan structure and attachment site identification.</title>
<authorList>
<person name="Nilsson J."/>
<person name="Rueetschi U."/>
<person name="Halim A."/>
<person name="Hesse C."/>
<person name="Carlsohn E."/>
<person name="Brinkmalm G."/>
<person name="Larson G."/>
</authorList>
<dbReference type="PubMed" id="19838169"/>
<dbReference type="DOI" id="10.1038/nmeth.1392"/>
</citation>
<scope>GLYCOSYLATION [LARGE SCALE ANALYSIS] AT THR-212; THR-307 AND SER-308</scope>
<scope>STRUCTURE OF CARBOHYDRATES</scope>
<source>
<tissue>Cerebrospinal fluid</tissue>
</source>
</reference>
<reference key="38">
<citation type="journal article" date="2010" name="Biochemistry" volume="49" first="1207" last="1216">
<title>Decoding of lipoprotein-receptor interactions: properties of ligand binding modules governing interactions with apolipoprotein E.</title>
<authorList>
<person name="Guttman M."/>
<person name="Prieto J.H."/>
<person name="Croy J.E."/>
<person name="Komives E.A."/>
</authorList>
<dbReference type="PubMed" id="20030366"/>
<dbReference type="DOI" id="10.1021/bi9017208"/>
</citation>
<scope>FUNCTION</scope>
<scope>LRP1-BINDING</scope>
<scope>REGION</scope>
</reference>
<reference key="39">
<citation type="journal article" date="2010" name="Mol. Cell. Proteomics" volume="9" first="1968" last="1981">
<title>Glycosylation and sialylation of macrophage-derived human apolipoprotein E analyzed by SDS-PAGE and mass spectrometry: evidence for a novel site of glycosylation on Ser290.</title>
<authorList>
<person name="Lee Y."/>
<person name="Kockx M."/>
<person name="Raftery M.J."/>
<person name="Jessup W."/>
<person name="Griffith R."/>
<person name="Kritharides L."/>
</authorList>
<dbReference type="PubMed" id="20511397"/>
<dbReference type="DOI" id="10.1074/mcp.m900430-mcp200"/>
</citation>
<scope>GLYCOSYLATION AT SER-308</scope>
</reference>
<reference key="40">
<citation type="journal article" date="2011" name="BMC Syst. Biol." volume="5" first="17" last="17">
<title>Initial characterization of the human central proteome.</title>
<authorList>
<person name="Burkard T.R."/>
<person name="Planyavsky M."/>
<person name="Kaupe I."/>
<person name="Breitwieser F.P."/>
<person name="Buerckstuemmer T."/>
<person name="Bennett K.L."/>
<person name="Superti-Furga G."/>
<person name="Colinge J."/>
</authorList>
<dbReference type="PubMed" id="21269460"/>
<dbReference type="DOI" id="10.1186/1752-0509-5-17"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="41">
<citation type="journal article" date="2012" name="J. Proteome Res." volume="11" first="4733" last="4743">
<title>Resveratrol-induced changes of the human adipocyte secretion profile.</title>
<authorList>
<person name="Rosenow A."/>
<person name="Noben J.P."/>
<person name="Jocken J."/>
<person name="Kallendrusch S."/>
<person name="Fischer-Posovszky P."/>
<person name="Mariman E.C."/>
<person name="Renes J."/>
</authorList>
<dbReference type="PubMed" id="22905912"/>
<dbReference type="DOI" id="10.1021/pr300539b"/>
</citation>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
</reference>
<reference key="42">
<citation type="journal article" date="2013" name="J. Clin. Invest." volume="123" first="2742" last="2751">
<title>Apolipoproteins E and AV mediate lipoprotein clearance by hepatic proteoglycans.</title>
<authorList>
<person name="Gonzales J.C."/>
<person name="Gordts P.L."/>
<person name="Foley E.M."/>
<person name="Esko J.D."/>
</authorList>
<dbReference type="PubMed" id="23676495"/>
<dbReference type="DOI" id="10.1172/jci67398"/>
</citation>
<scope>FUNCTION IN LIPOPROTEIN CLEARANCE</scope>
<scope>HEPARAN-SULFATE PROTEOGLYCANS BINDING</scope>
</reference>
<reference key="43">
<citation type="journal article" date="2013" name="J. Proteome Res." volume="12" first="573" last="584">
<title>LC-MS/MS characterization of O-glycosylation sites and glycan structures of human cerebrospinal fluid glycoproteins.</title>
<authorList>
<person name="Halim A."/>
<person name="Ruetschi U."/>
<person name="Larson G."/>
<person name="Nilsson J."/>
</authorList>
<dbReference type="PubMed" id="23234360"/>
<dbReference type="DOI" id="10.1021/pr300963h"/>
</citation>
<scope>GLYCOSYLATION AT THR-26; THR-36 AND SER-314</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="44">
<citation type="journal article" date="2013" name="Proc. Natl. Acad. Sci. U.S.A." volume="110" first="E1807" last="E1816">
<title>ApoE influences amyloid-beta (Abeta) clearance despite minimal apoE/Abeta association in physiological conditions.</title>
<authorList>
<person name="Verghese P.B."/>
<person name="Castellano J.M."/>
<person name="Garai K."/>
<person name="Wang Y."/>
<person name="Jiang H."/>
<person name="Shah A."/>
<person name="Bu G."/>
<person name="Frieden C."/>
<person name="Holtzman D.M."/>
</authorList>
<dbReference type="PubMed" id="23620513"/>
<dbReference type="DOI" id="10.1073/pnas.1220484110"/>
</citation>
<scope>FUNCTION IN CHOLESTEROL EFFLUX</scope>
<scope>INTERACTION WITH APP/A4 AMYLOID-BETA PEPTIDE</scope>
</reference>
<reference key="45">
<citation type="journal article" date="2014" name="J. Proteomics" volume="96" first="253" last="262">
<title>An enzyme assisted RP-RPLC approach for in-depth analysis of human liver phosphoproteome.</title>
<authorList>
<person name="Bian Y."/>
<person name="Song C."/>
<person name="Cheng K."/>
<person name="Dong M."/>
<person name="Wang F."/>
<person name="Huang J."/>
<person name="Sun D."/>
<person name="Wang L."/>
<person name="Ye M."/>
<person name="Zou H."/>
</authorList>
<dbReference type="PubMed" id="24275569"/>
<dbReference type="DOI" id="10.1016/j.jprot.2013.11.014"/>
</citation>
<scope>PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-147</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]</scope>
<source>
<tissue>Liver</tissue>
</source>
</reference>
<reference key="46">
<citation type="journal article" date="2014" name="J. Virol." volume="88" first="12422" last="12437">
<title>Apolipoprotein E likely contributes to a maturation step of infectious hepatitis C virus particles and interacts with viral envelope glycoproteins.</title>
<authorList>
<person name="Lee J.Y."/>
<person name="Acosta E.G."/>
<person name="Stoeck I.K."/>
<person name="Long G."/>
<person name="Hiet M.S."/>
<person name="Mueller B."/>
<person name="Fackler O.T."/>
<person name="Kallis S."/>
<person name="Bartenschlager R."/>
</authorList>
<dbReference type="PubMed" id="25122793"/>
<dbReference type="DOI" id="10.1128/jvi.01660-14"/>
</citation>
<scope>INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION)</scope>
<scope>FUNCTION MICROBIAL INFECTION)</scope>
</reference>
<reference key="47">
<citation type="journal article" date="2015" name="Cell" volume="161" first="1619" last="1632">
<title>A single kinase generates the majority of the secreted phosphoproteome.</title>
<authorList>
<person name="Tagliabracci V.S."/>
<person name="Wiley S.E."/>
<person name="Guo X."/>
<person name="Kinch L.N."/>
<person name="Durrant E."/>
<person name="Wen J."/>
<person name="Xiao J."/>
<person name="Cui J."/>
<person name="Nguyen K.B."/>
<person name="Engel J.L."/>
<person name="Coon J.J."/>
<person name="Grishin N."/>
<person name="Pinna L.A."/>
<person name="Pagliarini D.J."/>
<person name="Dixon J.E."/>
</authorList>
<dbReference type="PubMed" id="26091039"/>
<dbReference type="DOI" id="10.1016/j.cell.2015.05.028"/>
</citation>
<scope>PHOSPHORYLATION AT SER-147</scope>
</reference>
<reference key="48">
<citation type="journal article" date="2017" name="Cell" volume="168" first="427" last="441">
<title>ApoE2, ApoE3, and ApoE4 Differentially Stimulate APP Transcription and Abeta Secretion.</title>
<authorList>
<person name="Huang Y.A."/>
<person name="Zhou B."/>
<person name="Wernig M."/>
<person name="Suedhof T.C."/>
</authorList>
<dbReference type="PubMed" id="28111074"/>
<dbReference type="DOI" id="10.1016/j.cell.2016.12.044"/>
</citation>
<scope>FUNCTION IN APP TRANSCRIPTION</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="49">
<citation type="journal article" date="2018" name="J. Virol." volume="92" first="e00211" last="e00218">
<title>Regulation of Apolipoprotein E Trafficking by Hepatitis C Virus-Induced Autophagy.</title>
<authorList>
<person name="Kim J.Y."/>
<person name="Ou J.J."/>
</authorList>
<dbReference type="PubMed" id="29695434"/>
<dbReference type="DOI" id="10.1128/jvi.00211-18"/>
</citation>
<scope>INTERACTION WITH HCV ENVELOPE GLYCOPROTEIN E2 (MICROBIAL INFECTION)</scope>
<scope>FUNCTION (MICROBIAL INFECTION)</scope>
</reference>
<reference key="50" evidence="6">
<citation type="journal article" date="1991" name="Science" volume="252" first="1817" last="1822">
<title>Three-dimensional structure of the LDL receptor-binding domain of human apolipoprotein E.</title>
<authorList>
<person name="Wilson C."/>
<person name="Wardell M.R."/>
<person name="Weisgraber K.H."/>
<person name="Mahley R.W."/>
<person name="Agard D.A."/>
</authorList>
<dbReference type="PubMed" id="2063194"/>
<dbReference type="DOI" id="10.1126/science.2063194"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.25 ANGSTROMS) OF 41-184</scope>
<scope>FUNCTION</scope>
<scope>REGION</scope>
</reference>
<reference key="51" evidence="5">
<citation type="journal article" date="1994" name="J. Biol. Chem." volume="269" first="22358" last="22365">
<title>Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms.</title>
<authorList>
<person name="Dong L.M."/>
<person name="Wilson C."/>
<person name="Wardell M.R."/>
<person name="Simmons T."/>
<person name="Mahley R.W."/>
<person name="Weisgraber K.H."/>
<person name="Agard D.A."/>
</authorList>
<dbReference type="PubMed" id="8071364"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 41-184 OF VARIANT AD2 ARG-130</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
<scope>MUTAGENESIS OF ARG-79 AND GLU-127</scope>
<scope>REGION</scope>
</reference>
<reference key="52" evidence="4">
<citation type="journal article" date="1994" name="Structure" volume="2" first="713" last="718">
<title>Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein.</title>
<authorList>
<person name="Wilson C."/>
<person name="Mau T."/>
<person name="Weisgraber K.H."/>
<person name="Wardell M.R."/>
<person name="Mahley R.W."/>
<person name="Agard D.A."/>
</authorList>
<dbReference type="PubMed" id="7994571"/>
<dbReference type="DOI" id="10.1016/s0969-2126(00)00072-1"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 41-184 OF VARIANT CYS-176</scope>
<scope>CHARACTERIZATION OF VARIANT CYS-176</scope>
</reference>
<reference key="53" evidence="7 8">
<citation type="journal article" date="1996" name="Nat. Struct. Biol." volume="3" first="718" last="722">
<title>Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia.</title>
<authorList>
<person name="Dong L.-M."/>
<person name="Parkin S."/>
<person name="Trakhanov S.D."/>
<person name="Rupp B."/>
<person name="Simmons T."/>
<person name="Arnold K.S."/>
<person name="Newhouse Y.M."/>
<person name="Innerarity T.L."/>
<person name="Weisgraber K.H."/>
</authorList>
<dbReference type="PubMed" id="8756331"/>
<dbReference type="DOI" id="10.1038/nsb0896-718"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.0 ANGSTROMS) OF 19-209 OF VARIANT CYS-176</scope>
<scope>MUTAGENESIS OF ASP-172</scope>
<scope>CHARACTERIZATION OF VARIANT CYS-176</scope>
<scope>FUNCTION</scope>
<scope>LDLR-BINDING</scope>
</reference>
<reference key="54" evidence="2 10 11">
<citation type="journal article" date="2000" name="Protein Sci." volume="9" first="886" last="897">
<title>Conformational flexibility in the apolipoprotein E amino-terminal domain structure determined from three new crystal forms: implications for lipid binding.</title>
<authorList>
<person name="Segelke B.W."/>
<person name="Forstner M."/>
<person name="Knapp M."/>
<person name="Trakhanov S.D."/>
<person name="Parkin S."/>
<person name="Newhouse Y.M."/>
<person name="Bellamy H.D."/>
<person name="Weisgraber K.H."/>
<person name="Rupp B."/>
</authorList>
<dbReference type="PubMed" id="10850798"/>
<dbReference type="DOI" id="10.1110/ps.9.5.886"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 19-183</scope>
</reference>
<reference key="55" evidence="1">
<citation type="journal article" date="2001" name="Biochemistry" volume="40" first="2826" last="2834">
<title>Interaction of the N-terminal domain of apolipoprotein E4 with heparin.</title>
<authorList>
<person name="Dong J."/>
<person name="Peters-Libeu C.A."/>
<person name="Weisgraber K.H."/>
<person name="Segelke B.W."/>
<person name="Rupp B."/>
<person name="Capila I."/>
<person name="Hernaiz M.J."/>
<person name="LeBrun L.A."/>
<person name="Linhardt R.J."/>
</authorList>
<dbReference type="PubMed" id="11258893"/>
<dbReference type="DOI" id="10.1021/bi002417n"/>
</citation>
<scope>X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 19-209 OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="56" evidence="13">
<citation type="journal article" date="2010" name="J. Mol. Biol." volume="398" first="306" last="319">
<title>Structure of the minimal interface between ApoE and LRP.</title>
<authorList>
<person name="Guttman M."/>
<person name="Prieto J.H."/>
<person name="Handel T.M."/>
<person name="Domaille P.J."/>
<person name="Komives E.A."/>
</authorList>
<dbReference type="PubMed" id="20303980"/>
<dbReference type="DOI" id="10.1016/j.jmb.2010.03.022"/>
</citation>
<scope>STRUCTURE BY NMR OF 147-167 IN COMPLEX WITH LRP1</scope>
<scope>FUNCTION</scope>
<scope>LRP1-BINDING</scope>
</reference>
<reference key="57">
<citation type="journal article" date="1989" name="J. Biochem." volume="105" first="51" last="54">
<title>Identification of human apolipoprotein E variant gene: apolipoprotein E7 (Glu244,245----Lys244,245).</title>
<authorList>
<person name="Maeda H."/>
<person name="Nakamura H."/>
<person name="Kobori S."/>
<person name="Okada M."/>
<person name="Mori H."/>
<person name="Niki H."/>
<person name="Ogura T."/>
<person name="Hiraga S."/>
</authorList>
<dbReference type="PubMed" id="2738044"/>
<dbReference type="DOI" id="10.1093/oxfordjournals.jbchem.a122618"/>
</citation>
<scope>VARIANT HLPP3 262-GLU-GLU-263 DELINS LYS-LYS</scope>
</reference>
<reference key="58">
<citation type="journal article" date="1989" name="J. Biochem." volume="105" first="491" last="493">
<title>Molecular cloning of a human apolipoprotein E variant: E5 (Glu-3--&gt;Lys).</title>
<authorList>
<person name="Maeda H."/>
<person name="Nakamura H."/>
<person name="Kobori S."/>
<person name="Okada M."/>
<person name="Niki H."/>
<person name="Ogura T."/>
<person name="Hiraga S."/>
</authorList>
<dbReference type="PubMed" id="2760009"/>
<dbReference type="DOI" id="10.1093/oxfordjournals.jbchem.a122692"/>
</citation>
<scope>VARIANT LYS-21</scope>
</reference>
<reference key="59">
<citation type="journal article" date="1989" name="J. Biol. Chem." volume="264" first="21205" last="21210">
<title>Apolipoprotein E3-Leiden contains a seven-amino acid insertion that is a tandem repeat of residues 121-127.</title>
<authorList>
<person name="Wardell M.R."/>
<person name="Weisgraber K.H."/>
<person name="Havekes L.M."/>
<person name="Rall S.C. Jr."/>
</authorList>
<dbReference type="PubMed" id="2556398"/>
</citation>
<scope>VARIANTS HLPP3 ARG-130 AND GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS</scope>
</reference>
<reference key="60">
<citation type="journal article" date="1990" name="Jpn. J. Med." volume="29" first="587" last="594">
<title>Identification and characterization of a new variant of apolipoprotein E (apo E-Kochi).</title>
<authorList>
<person name="Suehiro T."/>
<person name="Yoshida K."/>
<person name="Yamano T."/>
<person name="Ohno F."/>
</authorList>
<dbReference type="PubMed" id="2101409"/>
<dbReference type="DOI" id="10.2169/internalmedicine1962.29.587"/>
</citation>
<scope>VARIANT HLPP3 HIS-163</scope>
</reference>
<reference key="61">
<citation type="journal article" date="1990" name="J. Lipid Res." volume="31" first="535" last="543">
<title>Apolipoprotein E2-Dunedin (228 Arg replaced by Cys): an apolipoprotein E2 variant with normal receptor-binding activity.</title>
<authorList>
<person name="Wardell M.R."/>
<person name="Rall S.C. Jr."/>
<person name="Brennan S.O."/>
<person name="Nye E.R."/>
<person name="George P.M."/>
<person name="Janus E.D."/>
<person name="Weisgraber K.H."/>
</authorList>
<dbReference type="PubMed" id="2341812"/>
</citation>
<scope>VARIANT CYS-246</scope>
</reference>
<reference key="62">
<citation type="journal article" date="1991" name="J. Biol. Chem." volume="266" first="10479" last="10484">
<title>Apolipoprotein E-4 Philadelphia (Glu-13--&gt;Lys,Arg-145--&gt;Cys). Homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia.</title>
<authorList>
<person name="Lohse P."/>
<person name="Mann W.A."/>
<person name="Stein E.A."/>
<person name="Brewer H.B. Jr."/>
</authorList>
<dbReference type="PubMed" id="1674745"/>
</citation>
<scope>VARIANTS HLPP3 LYS-31 AND CYS-163</scope>
</reference>
<reference key="63">
<citation type="journal article" date="1991" name="J. Lipid Res." volume="32" first="613" last="620">
<title>Characterization of a new apolipoprotein E5 variant detected in two French-Canadian subjects.</title>
<authorList>
<person name="Mailly F."/>
<person name="Xu C.F."/>
<person name="Xhignesse M."/>
<person name="Lussier-Cacan S."/>
<person name="Talmud P.J."/>
<person name="Davignon J."/>
<person name="Humphries S.E."/>
<person name="Nestruck A.C."/>
</authorList>
<dbReference type="PubMed" id="1713245"/>
</citation>
<scope>VARIANT APOE5 FRENCH-CANADIAN LYS-31</scope>
</reference>
<reference key="64">
<citation type="journal article" date="1992" name="Biochem. Biophys. Res. Commun." volume="187" first="1180" last="1186">
<title>Site-directed mutagenesis of an apolipoprotein E mutant, apo E5(Glu3----Lys) and its binding to low density lipoprotein receptors.</title>
<authorList>
<person name="Dong L.M."/>
<person name="Yamamura T."/>
<person name="Tajima S."/>
<person name="Yamamoto A."/>
</authorList>
<dbReference type="PubMed" id="1530612"/>
<dbReference type="DOI" id="10.1016/0006-291x(92)91321-g"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT LYS-21</scope>
<scope>FUNCTION</scope>
<scope>LDLR-BINDING</scope>
</reference>
<reference key="65">
<citation type="journal article" date="1992" name="J. Lipid Res." volume="33" first="1583" last="1590">
<title>Familial apolipoprotein E deficiency and type III hyperlipoproteinemia due to a premature stop codon in the apolipoprotein E gene.</title>
<authorList>
<person name="Lohse P."/>
<person name="Brewer H.B. III"/>
<person name="Meng M.S."/>
<person name="Skarlatos S.I."/>
<person name="LaRosa J.C."/>
<person name="Brewer H.B. Jr."/>
</authorList>
<dbReference type="PubMed" id="1361196"/>
</citation>
<scope>VARIANT HLPP3 228-TRP--HIS-317 DEL</scope>
</reference>
<reference key="66">
<citation type="journal article" date="1993" name="Am. J. Hum. Genet." volume="52" first="937" last="946">
<title>Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia.</title>
<authorList>
<person name="van den Maagdenberg A.M.J.M."/>
<person name="Weng W."/>
<person name="de Bruijn I.H."/>
<person name="de Knijff P."/>
<person name="Funke H."/>
<person name="Smelt A.H.M."/>
<person name="Leuven J.A.G."/>
<person name="van 't Hooft F.M."/>
<person name="Assmann G."/>
<person name="Hofker M.H."/>
<person name="Havekes L.M."/>
<person name="Frants R.R."/>
</authorList>
<dbReference type="PubMed" id="8488843"/>
</citation>
<scope>VARIANTS GLU-254; GLY-269; GLU-270; HIS-292 AND ARG-314</scope>
</reference>
<reference key="67">
<citation type="journal article" date="1993" name="Electrophoresis" volume="14" first="1032" last="1037">
<title>Characterization of the gene for apolipoprotein E5-Frankfurt (Gln81-&gt;Lys, Cys112-&gt;Arg) by polymerase chain reaction, restriction isotyping, and temperature gradient gel electrophoresis.</title>
<authorList>
<person name="Ruzicka V."/>
<person name="Maerz W."/>
<person name="Russ A."/>
<person name="Fisher E."/>
<person name="Mondorf W."/>
<person name="Gross W."/>
</authorList>
<dbReference type="PubMed" id="8125051"/>
<dbReference type="DOI" id="10.1002/elps.11501401164"/>
</citation>
<scope>VARIANTS LYS-99 AND ARG-130</scope>
</reference>
<reference key="68">
<citation type="journal article" date="1993" name="J. Lipid Res." volume="34" first="447" last="453">
<title>Preferential association of apolipoprotein E Leiden with very low density lipoproteins of human plasma.</title>
<authorList>
<person name="Fazio S."/>
<person name="Horie Y."/>
<person name="Weisgraber K.H."/>
<person name="Havekes L.M."/>
<person name="Rall S.C. Jr."/>
</authorList>
<dbReference type="PubMed" id="8468528"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT GLU-VAL-GLN-ALA-MET-LEU-GLY-145 INS</scope>
</reference>
<reference key="69">
<citation type="journal article" date="1993" name="Science" volume="261" first="921" last="923">
<title>Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families.</title>
<authorList>
<person name="Corder E.H."/>
<person name="Saunders A.M."/>
<person name="Strittmatter W.J."/>
<person name="Schmechel D.E."/>
<person name="Gaskell P.C."/>
<person name="Small G.W."/>
<person name="Roses A.D."/>
<person name="Haines J.L."/>
<person name="Pericak-Vance M.A."/>
</authorList>
<dbReference type="PubMed" id="8346443"/>
<dbReference type="DOI" id="10.1126/science.8346443"/>
</citation>
<scope>INVOLVEMENT IN AD2</scope>
<scope>VARIANT AD2 ARG-130</scope>
</reference>
<reference key="70">
<citation type="journal article" date="1994" name="Clin. Chem." volume="40" first="24" last="29">
<title>Common and rare genotypes of human apolipoprotein E determined by specific restriction profiles of polymerase chain reaction-amplified DNA.</title>
<authorList>
<person name="Richard P."/>
<person name="Thomas G."/>
<person name="de Zulueta M.P."/>
<person name="de Gennes J.-L."/>
<person name="Thomas M."/>
<person name="Cassaigne A."/>
<person name="Bereziat G."/>
<person name="Iron A."/>
</authorList>
<dbReference type="PubMed" id="8287539"/>
</citation>
<scope>VARIANTS HLPP3 ARG-130; SER-154; CYS-160 AND CYS-176</scope>
<scope>VARIANT ASP-145</scope>
</reference>
<reference key="71">
<citation type="journal article" date="1995" name="J. Clin. Invest." volume="96" first="1100" last="1107">
<title>Dominant expression of type III hyperlipoproteinemia. Pathophysiological insights derived from the structural and kinetic characteristics of ApoE-1 (Lys146--&gt;Glu).</title>
<authorList>
<person name="Mann W.A."/>
<person name="Lohse P."/>
<person name="Gregg R.E."/>
<person name="Ronan R."/>
<person name="Hoeg J.M."/>
<person name="Zech L.A."/>
<person name="Brewer H.B. Jr."/>
</authorList>
<dbReference type="PubMed" id="7635945"/>
<dbReference type="DOI" id="10.1172/jci118096"/>
</citation>
<scope>VARIANT HLPP3 GLU-164</scope>
<scope>CHARACTERIZATION OF VARIANT HLPP3 GLU-164 AND CYS-176</scope>
<scope>FUNCTION</scope>
<scope>LDLR-BINDING</scope>
<scope>HEPARIN-BINDING</scope>
</reference>
<reference key="72">
<citation type="journal article" date="1996" name="Biochim. Biophys. Acta" volume="1301" first="185" last="190">
<title>Characterization of a novel variant of apolipoprotein E, E2 Fukuoka (Arg-224 --&gt; Gln) in a hyperlipidemic patient with xanthomatosis.</title>
<authorList>
<person name="Moriyama K."/>
<person name="Sasaki J."/>
<person name="Takada Y."/>
<person name="Arakawa F."/>
<person name="Matsunaga A."/>
<person name="Ito Y."/>
<person name="Arakawa K."/>
</authorList>
<dbReference type="PubMed" id="8664327"/>
<dbReference type="DOI" id="10.1016/0005-2760(96)00014-8"/>
</citation>
<scope>VARIANT GLN-242</scope>
</reference>
<reference key="73">
<citation type="journal article" date="1997" name="J. Am. Soc. Nephrol." volume="8" first="820" last="823">
<title>Apolipoprotein E Sendai (arginine 145--&gt;proline): a new variant associated with lipoprotein glomerulopathy.</title>
<authorList>
<person name="Oikawa S."/>
<person name="Matsunaga A."/>
<person name="Saito T."/>
<person name="Sato H."/>
<person name="Seki T."/>
<person name="Hoshi K."/>
<person name="Hayasaka K."/>
<person name="Kotake H."/>
<person name="Midorikawa H."/>
<person name="Sekikawa A."/>
<person name="Hara S."/>
<person name="Abe K."/>
<person name="Toyota T."/>
<person name="Jingami H."/>
<person name="Nakamura H."/>
<person name="Sasaki J."/>
</authorList>
<dbReference type="PubMed" id="9176854"/>
</citation>
<scope>VARIANT LPG PRO-163</scope>
</reference>
<reference key="74">
<citation type="journal article" date="1997" name="Mutat. Res." volume="382" first="57" last="65">
<title>Apolipoprotein E R112; R251G: a carboxy-terminal variant found in patients with hyperlipidemia and coronary heart disease.</title>
<authorList>
<person name="Kang A.K."/>
<person name="Jenkins D.J.A."/>
<person name="Wolever T.M.S."/>
<person name="Huff M.W."/>
<person name="Maguire G.F."/>
<person name="Connelly P.W."/>
<person name="Hegele R.A."/>
</authorList>
<dbReference type="PubMed" id="9360638"/>
<dbReference type="DOI" id="10.1016/s1383-5726(97)00009-5"/>
</citation>
<scope>VARIANTS ARG-130 AND GLY-269</scope>
</reference>
<reference key="75">
<citation type="journal article" date="1999" name="Kidney Int." volume="56" first="421" last="427">
<title>A novel apolipoprotein E mutation, E2 (Arg25Cys), in lipoprotein glomerulopathy.</title>
<authorList>
<person name="Matsunaga A."/>
<person name="Sasaki J."/>
<person name="Komatsu T."/>
<person name="Kanatsu K."/>
<person name="Tsuji E."/>
<person name="Moriyama K."/>
<person name="Koga T."/>
<person name="Arakawa K."/>
<person name="Oikawa S."/>
<person name="Saito T."/>
<person name="Kita T."/>
<person name="Doi T."/>
</authorList>
<dbReference type="PubMed" id="10432380"/>
<dbReference type="DOI" id="10.1046/j.1523-1755.1999.00572.x"/>
</citation>
<scope>VARIANT LPG CYS-43</scope>
</reference>
<reference key="76">
<citation type="journal article" date="2000" name="J. Biol. Chem." volume="275" first="31269" last="31273">
<title>Virus-mediated transduction of apolipoprotein E (ApoE)-sendai develops lipoprotein glomerulopathy in ApoE-deficient mice.</title>
<authorList>
<person name="Ishigaki Y."/>
<person name="Oikawa S."/>
<person name="Suzuki T."/>
<person name="Usui S."/>
<person name="Magoori K."/>
<person name="Kim D.H."/>
<person name="Suzuki H."/>
<person name="Sasaki J."/>
<person name="Sasano H."/>
<person name="Okazaki M."/>
<person name="Toyota T."/>
<person name="Saito T."/>
<person name="Yamamoto T.T."/>
</authorList>
<dbReference type="PubMed" id="10903326"/>
<dbReference type="DOI" id="10.1074/jbc.m005906200"/>
</citation>
<scope>CHARACTERIZATION OF VARIANT LPG PRO-163</scope>
<scope>CHARACTERIZATION OF VARIANT AD2 ARG-130</scope>
</reference>
<reference key="77">
<citation type="journal article" date="2000" name="J. Clin. Endocrinol. Metab." volume="85" first="4354" last="4358">
<title>Familial splenomegaly: macrophage hypercatabolism of lipoproteins associated with apolipoprotein E mutation [apolipoprotein E (delta149 Leu)].</title>
<authorList>
<person name="Nguyen T.T."/>
<person name="Kruckeberg K.E."/>
<person name="O'Brien J.F."/>
<person name="Ji Z.-S."/>
<person name="Karnes P.S."/>
<person name="Crotty T.B."/>
<person name="Hay I.D."/>
<person name="Mahley R.W."/>
<person name="O'Brien T."/>
</authorList>
<dbReference type="PubMed" id="11095479"/>
<dbReference type="DOI" id="10.1210/jcem.85.11.6981"/>
</citation>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="78">
<citation type="journal article" date="2003" name="Eur. J. Clin. Invest." volume="33" first="677" last="685">
<title>Apolipoprotein E3Basel: new insights into a highly conserved protein region.</title>
<authorList>
<person name="Miserez A.R."/>
<person name="Scharnagl H."/>
<person name="Muller P.Y."/>
<person name="Mirsaidi R."/>
<person name="Stahelin H.B."/>
<person name="Monsch A."/>
<person name="Marz W."/>
<person name="Hoffmann M.M."/>
</authorList>
<dbReference type="PubMed" id="12864777"/>
<dbReference type="DOI" id="10.1046/j.1365-2362.2003.01180.x"/>
</citation>
<scope>VARIANT VAL-124</scope>
</reference>
<reference key="79">
<citation type="journal article" date="2003" name="Hum. Mol. Genet." volume="12" first="2733" last="2743">
<title>Association of extreme blood lipid profile phenotypic variation with 11 reverse cholesterol transport genes and 10 non-genetic cardiovascular disease risk factors.</title>
<authorList>
<person name="Morabia A."/>
<person name="Cayanis E."/>
<person name="Costanza M.C."/>
<person name="Ross B.M."/>
<person name="Flaherty M.S."/>
<person name="Alvin G.B."/>
<person name="Das K."/>
<person name="Gilliam T.C."/>
</authorList>
<dbReference type="PubMed" id="12966036"/>
<dbReference type="DOI" id="10.1093/hmg/ddg314"/>
</citation>
<scope>VARIANTS ARG-130 AND CYS-176</scope>
</reference>
<reference key="80">
<citation type="journal article" date="2005" name="Eur. J. Hum. Genet." volume="13" first="1186" last="1191">
<title>Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation.</title>
<authorList>
<person name="Faivre L."/>
<person name="Saugier-Veber P."/>
<person name="Pais de Barros J.-P."/>
<person name="Verges B."/>
<person name="Couret B."/>
<person name="Lorcerie B."/>
<person name="Thauvin C."/>
<person name="Charbonnier F."/>
<person name="Huet F."/>
<person name="Gambert P."/>
<person name="Frebourg T."/>
<person name="Duvillard L."/>
</authorList>
<dbReference type="PubMed" id="16094309"/>
<dbReference type="DOI" id="10.1038/sj.ejhg.5201480"/>
</citation>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="81">
<citation type="journal article" date="2007" name="N. Engl. J. Med." volume="357" first="2522" last="2524">
<title>APOE Kyoto mutation in European Americans with lipoprotein glomerulopathy.</title>
<authorList>
<person name="Rovin B.H."/>
<person name="Roncone D."/>
<person name="McKinley A."/>
<person name="Nadasdy T."/>
<person name="Korbet S.M."/>
<person name="Schwartz M.M."/>
</authorList>
<dbReference type="PubMed" id="18077821"/>
<dbReference type="DOI" id="10.1056/nejmc072088"/>
</citation>
<scope>VARIANT LPG CYS-43</scope>
</reference>
<reference key="82">
<citation type="journal article" date="2011" name="J. Mol. Cell Biol." volume="3" first="309" last="315">
<title>Quantitative detection of single amino acid polymorphisms by targeted proteomics.</title>
<authorList>
<person name="Su Z.D."/>
<person name="Sun L."/>
<person name="Yu D.X."/>
<person name="Li R.X."/>
<person name="Li H.X."/>
<person name="Yu Z.J."/>
<person name="Sheng Q.H."/>
<person name="Lin X."/>
<person name="Zeng R."/>
<person name="Wu J.R."/>
</authorList>
<dbReference type="PubMed" id="22028381"/>
<dbReference type="DOI" id="10.1093/jmcb/mjr024"/>
</citation>
<scope>VARIANT HIS-64</scope>
<scope>IDENTIFICATION BY MASS SPECTROMETRY</scope>
</reference>
<reference key="83">
<citation type="journal article" date="2012" name="Atherosclerosis" volume="222" first="449" last="455">
<title>Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia.</title>
<authorList>
<person name="Solanas-Barca M."/>
<person name="de Castro-Oros I."/>
<person name="Mateo-Gallego R."/>
<person name="Cofan M."/>
<person name="Plana N."/>
<person name="Puzo J."/>
<person name="Burillo E."/>
<person name="Martin-Fuentes P."/>
<person name="Ros E."/>
<person name="Masana L."/>
<person name="Pocovi M."/>
<person name="Civeira F."/>
<person name="Cenarro A."/>
</authorList>
<dbReference type="PubMed" id="22481068"/>
<dbReference type="DOI" id="10.1016/j.atherosclerosis.2012.03.011"/>
</citation>
<scope>VARIANT HLPP3 SER-154</scope>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="84">
<citation type="journal article" date="2013" name="Atherosclerosis" volume="231" first="218" last="222">
<title>APOE p.Leu167del mutation in familial hypercholesterolemia.</title>
<authorList>
<person name="Awan Z."/>
<person name="Choi H.Y."/>
<person name="Stitziel N."/>
<person name="Ruel I."/>
<person name="Bamimore M.A."/>
<person name="Husa R."/>
<person name="Gagnon M.H."/>
<person name="Wang R.H."/>
<person name="Peloso G.M."/>
<person name="Hegele R.A."/>
<person name="Seidah N.G."/>
<person name="Kathiresan S."/>
<person name="Genest J."/>
</authorList>
<dbReference type="PubMed" id="24267230"/>
<dbReference type="DOI" id="10.1016/j.atherosclerosis.2013.09.007"/>
</citation>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="85">
<citation type="journal article" date="2013" name="Hum. Mutat." volume="34" first="83" last="87">
<title>Description of a large family with autosomal dominant hypercholesterolemia associated with the APOE p.Leu167del mutation.</title>
<authorList>
<person name="Marduel M."/>
<person name="Ouguerram K."/>
<person name="Serre V."/>
<person name="Bonnefont-Rousselot D."/>
<person name="Marques-Pinheiro A."/>
<person name="Erik Berge K."/>
<person name="Devillers M."/>
<person name="Luc G."/>
<person name="Lecerf J.M."/>
<person name="Tosolini L."/>
<person name="Erlich D."/>
<person name="Peloso G.M."/>
<person name="Stitziel N."/>
<person name="Nitchke P."/>
<person name="Jais J.P."/>
<person name="Abifadel M."/>
<person name="Kathiresan S."/>
<person name="Leren T.P."/>
<person name="Rabes J.P."/>
<person name="Boileau C."/>
<person name="Varret M."/>
</authorList>
<dbReference type="PubMed" id="22949395"/>
<dbReference type="DOI" id="10.1002/humu.22215"/>
</citation>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="86">
<citation type="journal article" date="2016" name="J. Lipid Res." volume="57" first="482" last="491">
<title>Global molecular analysis and APOE mutations in a cohort of autosomal dominant hypercholesterolemia patients in France.</title>
<authorList>
<person name="Wintjens R."/>
<person name="Bozon D."/>
<person name="Belabbas K."/>
<person name="Mbou F."/>
<person name="Girardet J.P."/>
<person name="Tounian P."/>
<person name="Jolly M."/>
<person name="Boccara F."/>
<person name="Cohen A."/>
<person name="Karsenty A."/>
<person name="Dubern B."/>
<person name="Carel J.C."/>
<person name="Azar-Kolakez A."/>
<person name="Feillet F."/>
<person name="Labarthe F."/>
<person name="Gorsky A.M."/>
<person name="Horovitz A."/>
<person name="Tamarindi C."/>
<person name="Kieffer P."/>
<person name="Lienhardt A."/>
<person name="Lascols O."/>
<person name="Di Filippo M."/>
<person name="Dufernez F."/>
</authorList>
<dbReference type="PubMed" id="26802169"/>
<dbReference type="DOI" id="10.1194/jlr.p055699"/>
</citation>
<scope>VARIANTS PRO-46 AND ASP-145</scope>
<scope>VARIANT HLPP3 CYS-163</scope>
<scope>VARIANT SBHD LEU-167 DEL</scope>
</reference>
<reference key="87">
<citation type="journal article" date="1994" name="Hum. Mutat." volume="4" first="178" last="194">
<title>Genetic heterogeneity of apolipoprotein E and its influence on plasma lipid and lipoprotein levels.</title>
<authorList>
<person name="de Knijff P."/>
<person name="van den Maagdenberg A.M.J.M."/>
<person name="Frants R.R."/>
<person name="Havekes L.M."/>
</authorList>
<dbReference type="PubMed" id="7833947"/>
<dbReference type="DOI" id="10.1002/humu.1380040303"/>
</citation>
<scope>REVIEW</scope>
<scope>VARIANTS LYS-31; ARG-102; ARG-130; GLN-152 AND CYS-154</scope>
</reference>
<reference key="88">
<citation type="journal article" date="2014" name="Neurobiol. Dis." volume="72" first="3" last="12">
<title>Apolipoprotein E: structure and function in lipid metabolism, neurobiology, and Alzheimer's diseases.</title>
<authorList>
<person name="Huang Y."/>
<person name="Mahley R.W."/>
</authorList>
<dbReference type="PubMed" id="25173806"/>
<dbReference type="DOI" id="10.1016/j.nbd.2014.08.025"/>
</citation>
<scope>REVIEW</scope>
<scope>POLYMORPHISM</scope>
<scope>TISSUE SPECIFICITY</scope>
</reference>
<reference key="89">
<citation type="journal article" date="2018" name="J. Mol. Med." volume="96" first="361" last="371">
<title>Cell-specific production, secretion, and function of apolipoprotein E.</title>
<authorList>
<person name="Kockx M."/>
<person name="Traini M."/>
<person name="Kritharides L."/>
</authorList>
<dbReference type="PubMed" id="29516132"/>
<dbReference type="DOI" id="10.1007/s00109-018-1632-y"/>
</citation>
<scope>REVIEW</scope>
<scope>FUNCTION</scope>
<scope>PTM</scope>
</reference>
<comment type="function">
<text evidence="17 27 30 31 36 37 39 40 42 50 51 60 61 71 73 74 87 88 91 92 94 95">APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids (PubMed:6860692, PubMed:1911868, PubMed:14754908). APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance (PubMed:6860692, PubMed:2762297, PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:14754908, PubMed:23620513). Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma (PubMed:6860692, PubMed:2762297, PubMed:9395455). As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL) (PubMed:6860692, PubMed:1911868). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles (PubMed:2762297, PubMed:1917954, PubMed:7768901, PubMed:8939961, PubMed:12950167, PubMed:20030366, PubMed:2063194, PubMed:8756331, PubMed:20303980, PubMed:1530612, PubMed:7635945). Finally, APOE has also a heparin-binding activity and binds heparan-sulfate proteoglycans on the surface of cells, a property that supports the capture and the receptor-mediated uptake of APOE-containing lipoproteins by cells (PubMed:9395455, PubMed:9488694, PubMed:23676495, PubMed:7635945). A main function of APOE is to mediate lipoprotein clearance through the uptake of chylomicrons, VLDLs, and HDLs by hepatocytes (PubMed:1911868, PubMed:1917954, PubMed:9395455, PubMed:23676495, PubMed:29516132). APOE is also involved in the biosynthesis by the liver of VLDLs as well as their uptake by peripheral tissues ensuring the delivery of triglycerides and energy storage in muscle, heart and adipose tissues (PubMed:2762297, PubMed:29516132). By participating in the lipoprotein-mediated distribution of lipids among tissues, APOE plays a critical role in plasma and tissues lipid homeostasis (PubMed:2762297, PubMed:1917954, PubMed:29516132). APOE is also involved in two steps of reverse cholesterol transport, the HDLs-mediated transport of cholesterol from peripheral tissues to the liver, and thereby plays an important role in cholesterol homeostasis (PubMed:9395455, PubMed:14754908, PubMed:23620513). First, it is functionally associated with ABCA1 in the biogenesis of HDLs in tissues (PubMed:14754908, PubMed:23620513). Second, it is enriched in circulating HDLs and mediates their uptake by hepatocytes (PubMed:9395455). APOE also plays an important role in lipid transport in the central nervous system, regulating neuron survival and sprouting (PubMed:8939961, PubMed:25173806). APOE in also involved in innate and adaptive immune responses, controlling for instance the survival of myeloid-derived suppressor cells (By similarity). APOE, may also play a role in transcription regulation through a receptor-dependent and cholesterol-independent mechanism, that activates MAP3K12 and a non-canonical MAPK signal transduction pathway that results in enhanced AP-1-mediated transcription of APP (PubMed:28111074).</text>
</comment>
<comment type="function">
<text evidence="54 63">(Microbial infection) Through its interaction with HCV envelope glycoprotein E2, participates in the attachment of HCV to HSPGs and other receptors (LDLr, VLDLr, and SR-B1) on the cell surface and to the assembly, maturation and infectivity of HCV viral particles (PubMed:25122793, PubMed:29695434). This interaction is probably promoted via the up-regulation of cellular autophagy by the virus (PubMed:29695434).</text>
</comment>
<comment type="subunit">
<text evidence="30 50 65 75 76 81 83">Homotetramer (PubMed:8340399). May interact with ABCA1; functionally associated with ABCA1 in the biogenesis of HDLs (PubMed:14754908). May interact with APP/A4 amyloid-beta peptide; the interaction is extremely stable in vitro but its physiological significance is unclear (PubMed:8367470, PubMed:23620513). May interact with MAPT (PubMed:7972031). May interact with MAP2 (PubMed:7891887). In the cerebrospinal fluid, interacts with secreted SORL1 (PubMed:30448281).</text>
</comment>
<comment type="subunit">
<text evidence="54 63">(Microbial infection) Interacts with hepatitis C virus (HCV) envelope glycoprotein E2; this interaction is required for HCV infectivity and production.</text>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-2431589">
<id>PRO_0000000093</id>
<label>APP</label>
<dbReference type="UniProtKB" id="P05067"/>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-295634">
<id>Q16543</id>
<label>CDC37</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-1223708">
<id>P08603</id>
<label>CFH</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>8</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-2880701">
<id>Q9UBD9</id>
<label>CLCF1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-712452">
<id>Q9BQ95</id>
<label>ECSIT</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-1220767">
<id>P00738</id>
<label>HP</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>7</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-988319">
<id>P01130</id>
<label>LDLR</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-1046087">
<id>Q07954</id>
<label>LRP1</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>23</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-2681187">
<id>Q14114</id>
<label>LRP8</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>2</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-935824">
<id>Q53EL6</id>
<label>PDCD4</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-985879">
<id>P37840</id>
<label>SNCA</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>11</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-357285">
<id>P50502</id>
<label>ST13</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-726731">
<id>O75069</id>
<label>TMCC2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>5</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-14036387">
<id>Q9NZC2</id>
<label>TREM2</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-1222467">
<id>P02649</id>
</interactant>
<interactant intactId="EBI-6904269">
<id>PRO_0000037570</id>
<dbReference type="UniProtKB" id="P27958"/>
</interactant>
<organismsDiffer>true</organismsDiffer>
<experiments>4</experiments>
</comment>
<comment type="interaction">
<interactant intactId="EBI-9209835">
<id>PRO_0000001987</id>
</interactant>
<interactant intactId="EBI-366182">
<id>P10636</id>
<label>MAPT</label>
</interactant>
<organismsDiffer>false</organismsDiffer>
<experiments>3</experiments>
</comment>
<comment type="subcellular location">
<subcellularLocation>
<location evidence="53">Secreted</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="81">Secreted</location>
<location evidence="81">Extracellular space</location>
</subcellularLocation>
<subcellularLocation>
<location evidence="92">Secreted</location>
<location evidence="92">Extracellular space</location>
<location evidence="92">Extracellular matrix</location>
</subcellularLocation>
<text evidence="36 81 92">In the plasma, APOE is associated with chylomicrons, chylomicrons remnants, VLDL, LDL and HDL lipoproteins (PubMed:1911868, PubMed:8340399). Lipid poor oligomeric APOE is associated with the extracellular matrix in a calcium- and heparan-sulfate proteoglycans-dependent manner (PubMed:9488694). Lipidation induces the release from the extracellular matrix (PubMed:9488694).</text>
</comment>
<comment type="tissue specificity">
<text evidence="18 66 94">Produced by several tissues and cell types and mainly found associated with lipid particles in the plasma, the interstitial fluid and lymph (PubMed:25173806). Mainly synthesized by liver hepatocytes (PubMed:25173806). Significant quantities are also produced in brain, mainly by astrocytes and glial cells in the cerebral cortex, but also by neurons in frontal cortex and hippocampus (PubMed:3115992, PubMed:10027417). It is also expressed by cells of the peripheral nervous system (PubMed:10027417, PubMed:25173806). Also expressed by adrenal gland, testis, ovary, skin, kidney, spleen and adipose tissue and macrophages in various tissues (PubMed:25173806).</text>
</comment>
<comment type="PTM">
<text evidence="38 41 48 53 95">APOE exists as multiple glycosylated and sialylated glycoforms within cells and in plasma (PubMed:29516132). The extent of glycosylation and sialylation are tissue and context specific (PubMed:29516132). Plasma APOE undergoes desialylation and is less glycosylated and sialylated than the cellular form (PubMed:2498325, PubMed:19838169, PubMed:20511397, PubMed:23234360). Glycosylation is not required for proper expression and secretion (PubMed:2498325). O-glycosylated with core 1 or possibly core 8 glycans. Thr-307 and Ser-314 are minor glycosylation sites compared to Ser-308 (PubMed:19838169, PubMed:23234360).</text>
</comment>
<comment type="PTM">
<text evidence="20">Glycated in plasma VLDL of normal subjects, and of hyperglycemic diabetic patients at a higher level (2-3 fold).</text>
</comment>
<comment type="PTM">
<text evidence="56">Phosphorylated by FAM20C in the extracellular medium.</text>
</comment>
<comment type="PTM">
<text evidence="25">Undergoes C-terminal proteolytic processing in neurons. C-terminally truncated APOE has a tendency to form neurotoxic intracellular neurofibrillary tangle-like inclusions in neurons.</text>
</comment>
<comment type="polymorphism">
<text evidence="64 67 69 94">There are three common APOE alleles identified: APOE*2/APOE-epsilon2/E2, APOE*3/APOE-epsilon3/E3, and APOE*4/APOE-epsilon4/E4. The corresponding ApoE2, ApoE3 and ApoE4 isoforms differentially present Cys and Arg residues at positions 130 and 176. The most common allele in the human population is APOE*3 which sequence is the one displayed in that entry with a Cys at position 130 and an Arg at position 176. Common APOE variants influence lipoprotein metabolism in healthy individuals. Additional variants have been described and are described relative to the three common alleles.</text>
</comment>
<comment type="disease" evidence="29 33 43 45 55 57 58 73 80">
<disease id="DI-01771">
<name>Hyperlipoproteinemia 3</name>
<acronym>HLPP3</acronym>
<description>A disorder characterized by the accumulation of intermediate-density lipoprotein particles (IDL or broad-beta-lipoprotein) rich in cholesterol. Clinical features include xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause.</description>
<dbReference type="MIM" id="617347"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD.</text>
</comment>
<comment type="disease" evidence="21 24 25 61 64 75 76 78 82 83 88">
<disease id="DI-02694">
<name>Alzheimer disease 2</name>
<acronym>AD2</acronym>
<description>A late-onset form of Alzheimer disease. Alzheimer disease is a neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituents of these plaques are neurotoxic amyloid-beta protein 40 and amyloid-beta protein 42, that are produced by the proteolysis of the transmembrane APP protein. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products, such as C31, are also implicated in neuronal death.</description>
<dbReference type="MIM" id="104310"/>
</disease>
<text evidence="82">Disease susceptibility is associated with variations affecting the gene represented in this entry. The APOE*4 allele (APOE form E4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known.</text>
</comment>
<comment type="disease" evidence="23 32 45 47 52 57">
<disease id="DI-02290">
<name>Sea-blue histiocyte disease</name>
<acronym>SBHD</acronym>
<description>Characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses.</description>
<dbReference type="MIM" id="269600"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="disease" evidence="19 21 35 89">
<disease id="DI-01910">
<name>Lipoprotein glomerulopathy</name>
<acronym>LPG</acronym>
<description>Uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries.</description>
<dbReference type="MIM" id="611771"/>
</disease>
<text>The disease is caused by mutations affecting the gene represented in this entry.</text>
</comment>
<comment type="similarity">
<text evidence="97">Belongs to the apolipoprotein A1/A4/E family.</text>
</comment>
<comment type="online information" name="SHMPD">
<link uri="http://shmpd.bii.a-star.edu.sg/gene.php?genestart=A&amp;genename=APOE"/>
<text>The Singapore human mutation and polymorphism database</text>
</comment>
<comment type="online information" name="Wikipedia">
<link uri="https://en.wikipedia.org/wiki/Apolipoprotein_E"/>
<text>Apolipoprotein E entry</text>
</comment>
<comment type="online information" name="Protein Spotlight">
<link uri="https://web.expasy.org/spotlight/back_issues/083"/>
<text>Tangled - Issue 83 of June 2007</text>
</comment>
<dbReference type="EMBL" id="M12529">
<property type="protein sequence ID" value="AAB59518.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="K00396">
<property type="protein sequence ID" value="AAB59546.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="M10065">
<property type="protein sequence ID" value="AAB59397.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF050154">
<property type="protein sequence ID" value="AAD02505.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AF261279">
<property type="protein sequence ID" value="AAG27089.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="AK314898">
<property type="protein sequence ID" value="BAG37412.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="FJ525876">
<property type="protein sequence ID" value="ACN81314.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="EMBL" id="BC003557">
<property type="protein sequence ID" value="AAH03557.1"/>
<property type="molecule type" value="mRNA"/>
</dbReference>
<dbReference type="EMBL" id="AB035149">
<property type="protein sequence ID" value="BAA96080.1"/>
<property type="molecule type" value="Genomic_DNA"/>
</dbReference>
<dbReference type="CCDS" id="CCDS12647.1"/>
<dbReference type="PIR" id="A92478">
<property type="entry name" value="LPHUE"/>
</dbReference>
<dbReference type="RefSeq" id="NP_000032.1">
<property type="nucleotide sequence ID" value="NM_000041.3"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001289617.1">
<property type="nucleotide sequence ID" value="NM_001302688.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001289618.1">
<property type="nucleotide sequence ID" value="NM_001302689.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001289619.1">
<property type="nucleotide sequence ID" value="NM_001302690.1"/>
</dbReference>
<dbReference type="RefSeq" id="NP_001289620.1">
<property type="nucleotide sequence ID" value="NM_001302691.1"/>
</dbReference>
<dbReference type="PDB" id="1B68">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=19-209"/>
</dbReference>
<dbReference type="PDB" id="1BZ4">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.85"/>
<property type="chains" value="A=40-183"/>
</dbReference>
<dbReference type="PDB" id="1EA8">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.95"/>
<property type="chains" value="A=19-209"/>
</dbReference>
<dbReference type="PDB" id="1GS9">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.70"/>
<property type="chains" value="A=19-183"/>
</dbReference>
<dbReference type="PDB" id="1H7I">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.90"/>
<property type="chains" value="A=19-209"/>
</dbReference>
<dbReference type="PDB" id="1LE2">
<property type="method" value="X-ray"/>
<property type="resolution" value="3.00"/>
<property type="chains" value="A=41-184"/>
</dbReference>
<dbReference type="PDB" id="1LE4">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=41-184"/>
</dbReference>
<dbReference type="PDB" id="1LPE">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.25"/>
<property type="chains" value="A=41-184"/>
</dbReference>
<dbReference type="PDB" id="1NFN">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.80"/>
<property type="chains" value="A=19-209"/>
</dbReference>
<dbReference type="PDB" id="1NFO">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.00"/>
<property type="chains" value="A=19-209"/>
</dbReference>
<dbReference type="PDB" id="1OEF">
<property type="method" value="NMR"/>
<property type="chains" value="A=281-304"/>
</dbReference>
<dbReference type="PDB" id="1OEG">
<property type="method" value="NMR"/>
<property type="chains" value="A=285-307"/>
</dbReference>
<dbReference type="PDB" id="1OR2">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A=19-183"/>
</dbReference>
<dbReference type="PDB" id="1OR3">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.73"/>
<property type="chains" value="A=19-183"/>
</dbReference>
<dbReference type="PDB" id="2KC3">
<property type="method" value="NMR"/>
<property type="chains" value="A=19-201"/>
</dbReference>
<dbReference type="PDB" id="2KNY">
<property type="method" value="NMR"/>
<property type="chains" value="A=147-167"/>
</dbReference>
<dbReference type="PDB" id="2L7B">
<property type="method" value="NMR"/>
<property type="chains" value="A=19-317"/>
</dbReference>
<dbReference type="PDB" id="6IWB">
<property type="method" value="X-ray"/>
<property type="resolution" value="2.50"/>
<property type="chains" value="A/C=41-186"/>
</dbReference>
<dbReference type="PDB" id="6NCN">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.82"/>
<property type="chains" value="A=19-180"/>
</dbReference>
<dbReference type="PDB" id="6NCO">
<property type="method" value="X-ray"/>
<property type="resolution" value="1.71"/>
<property type="chains" value="A=19-180"/>
</dbReference>
<dbReference type="PDBsum" id="1B68"/>
<dbReference type="PDBsum" id="1BZ4"/>
<dbReference type="PDBsum" id="1EA8"/>
<dbReference type="PDBsum" id="1GS9"/>
<dbReference type="PDBsum" id="1H7I"/>
<dbReference type="PDBsum" id="1LE2"/>
<dbReference type="PDBsum" id="1LE4"/>
<dbReference type="PDBsum" id="1LPE"/>
<dbReference type="PDBsum" id="1NFN"/>
<dbReference type="PDBsum" id="1NFO"/>
<dbReference type="PDBsum" id="1OEF"/>
<dbReference type="PDBsum" id="1OEG"/>
<dbReference type="PDBsum" id="1OR2"/>
<dbReference type="PDBsum" id="1OR3"/>
<dbReference type="PDBsum" id="2KC3"/>
<dbReference type="PDBsum" id="2KNY"/>
<dbReference type="PDBsum" id="2L7B"/>
<dbReference type="PDBsum" id="6IWB"/>
<dbReference type="PDBsum" id="6NCN"/>
<dbReference type="PDBsum" id="6NCO"/>
<dbReference type="BMRB" id="P02649"/>
<dbReference type="SASBDB" id="P02649"/>
<dbReference type="SMR" id="P02649"/>
<dbReference type="BioGRID" id="106845">
<property type="interactions" value="137"/>
</dbReference>
<dbReference type="DIP" id="DIP-1120N"/>
<dbReference type="IntAct" id="P02649">
<property type="interactions" value="59"/>
</dbReference>
<dbReference type="MINT" id="P02649"/>
<dbReference type="STRING" id="9606.ENSP00000252486"/>
<dbReference type="DrugBank" id="DB09130">
<property type="generic name" value="Copper"/>
</dbReference>
<dbReference type="DrugBank" id="DB01593">
<property type="generic name" value="Zinc"/>
</dbReference>
<dbReference type="DrugBank" id="DB14487">
<property type="generic name" value="Zinc acetate"/>
</dbReference>
<dbReference type="DrugBank" id="DB14533">
<property type="generic name" value="Zinc chloride"/>
</dbReference>
<dbReference type="DrugBank" id="DB14548">
<property type="generic name" value="Zinc sulfate, unspecified form"/>
</dbReference>
<dbReference type="MoonDB" id="P02649">
<property type="type" value="Predicted"/>
</dbReference>
<dbReference type="CarbonylDB" id="P02649"/>
<dbReference type="GlyConnect" id="648">
<property type="glycosylation" value="2 O-Linked glycans (5 sites)"/>
</dbReference>
<dbReference type="GlyGen" id="P02649">
<property type="glycosylation" value="7 sites, 3 O-linked glycans (7 sites)"/>
</dbReference>
<dbReference type="iPTMnet" id="P02649"/>
<dbReference type="MetOSite" id="P02649"/>
<dbReference type="PhosphoSitePlus" id="P02649"/>
<dbReference type="SwissPalm" id="P02649"/>
<dbReference type="UniCarbKB" id="P02649"/>
<dbReference type="BioMuta" id="APOE"/>
<dbReference type="DMDM" id="114039"/>
<dbReference type="DOSAC-COBS-2DPAGE" id="P02649"/>
<dbReference type="SWISS-2DPAGE" id="P02649"/>
<dbReference type="CPTAC" id="non-CPTAC-1087"/>
<dbReference type="EPD" id="P02649"/>
<dbReference type="jPOST" id="P02649"/>
<dbReference type="MassIVE" id="P02649"/>
<dbReference type="MaxQB" id="P02649"/>
<dbReference type="PaxDb" id="P02649"/>
<dbReference type="PeptideAtlas" id="P02649"/>
<dbReference type="PRIDE" id="P02649"/>
<dbReference type="ProteomicsDB" id="51537"/>
<dbReference type="ABCD" id="P02649">
<property type="antibodies" value="7 sequenced antibodies"/>
</dbReference>
<dbReference type="Antibodypedia" id="3639">
<property type="antibodies" value="1399 antibodies"/>
</dbReference>
<dbReference type="DNASU" id="348"/>
<dbReference type="Ensembl" id="ENST00000252486">
<property type="protein sequence ID" value="ENSP00000252486"/>
<property type="gene ID" value="ENSG00000130203"/>
</dbReference>
<dbReference type="GeneID" id="348"/>
<dbReference type="KEGG" id="hsa:348"/>
<dbReference type="UCSC" id="uc002pab.4">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="CTD" id="348"/>
<dbReference type="DisGeNET" id="348"/>
<dbReference type="EuPathDB" id="HostDB:ENSG00000130203.9"/>
<dbReference type="GeneCards" id="APOE"/>
<dbReference type="GeneReviews" id="APOE"/>
<dbReference type="HGNC" id="HGNC:613">
<property type="gene designation" value="APOE"/>
</dbReference>
<dbReference type="HPA" id="ENSG00000130203">
<property type="expression patterns" value="Tissue enhanced (adrenal gland, liver)"/>
</dbReference>
<dbReference type="MalaCards" id="APOE"/>
<dbReference type="MIM" id="104310">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="107741">
<property type="type" value="gene"/>
</dbReference>
<dbReference type="MIM" id="269600">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="611771">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="MIM" id="617347">
<property type="type" value="phenotype"/>
</dbReference>
<dbReference type="neXtProt" id="NX_P02649"/>
<dbReference type="NIAGADS" id="ENSG00000130203"/>
<dbReference type="OpenTargets" id="ENSG00000130203"/>
<dbReference type="Orphanet" id="412">
<property type="disease" value="Dysbetalipoproteinemia"/>
</dbReference>
<dbReference type="Orphanet" id="329481">
<property type="disease" value="Lipoprotein glomerulopathy"/>
</dbReference>
<dbReference type="Orphanet" id="238616">
<property type="disease" value="NON RARE IN EUROPE: Alzheimer disease"/>
</dbReference>
<dbReference type="Orphanet" id="1648">
<property type="disease" value="NON RARE IN EUROPE: Dementia with Lewy body"/>
</dbReference>
<dbReference type="Orphanet" id="406">
<property type="disease" value="NON RARE IN EUROPE: Heterozygous familial hypercholesterolemia"/>
</dbReference>
<dbReference type="Orphanet" id="158029">
<property type="disease" value="Sea-blue histiocytosis"/>
</dbReference>
<dbReference type="PharmGKB" id="PA55"/>
<dbReference type="eggNOG" id="ENOG502QVD6">
<property type="taxonomic scope" value="Eukaryota"/>
</dbReference>
<dbReference type="GeneTree" id="ENSGT00950000182929"/>
<dbReference type="HOGENOM" id="CLU_066029_0_0_1"/>
<dbReference type="InParanoid" id="P02649"/>
<dbReference type="KO" id="K04524"/>
<dbReference type="OMA" id="ARLKGWF"/>
<dbReference type="OrthoDB" id="331262at2759"/>
<dbReference type="PhylomeDB" id="P02649"/>
<dbReference type="TreeFam" id="TF334458"/>
<dbReference type="PathwayCommons" id="P02649"/>
<dbReference type="Reactome" id="R-HSA-1251985">
<property type="pathway name" value="Nuclear signaling by ERBB4"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-3000480">
<property type="pathway name" value="Scavenging by Class A Receptors"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-381426">
<property type="pathway name" value="Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8864260">
<property type="pathway name" value="Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8957275">
<property type="pathway name" value="Post-translational protein phosphorylation"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8963888">
<property type="pathway name" value="Chylomicron assembly"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8963901">
<property type="pathway name" value="Chylomicron remodeling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8964026">
<property type="pathway name" value="Chylomicron clearance"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-8964058">
<property type="pathway name" value="HDL remodeling"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-9029569">
<property type="pathway name" value="NR1H3 &amp; NR1H2 regulate gene expression linked to cholesterol transport and efflux"/>
</dbReference>
<dbReference type="Reactome" id="R-HSA-975634">
<property type="pathway name" value="Retinoid metabolism and transport"/>
</dbReference>
<dbReference type="SIGNOR" id="P02649"/>
<dbReference type="BioGRID-ORCS" id="348">
<property type="hits" value="8 hits in 870 CRISPR screens"/>
</dbReference>
<dbReference type="ChiTaRS" id="APOE">
<property type="organism name" value="human"/>
</dbReference>
<dbReference type="EvolutionaryTrace" id="P02649"/>
<dbReference type="GeneWiki" id="Apolipoprotein_E"/>
<dbReference type="GenomeRNAi" id="348"/>
<dbReference type="Pharos" id="P02649">
<property type="development level" value="Tbio"/>
</dbReference>
<dbReference type="PRO" id="PR:P02649"/>
<dbReference type="Proteomes" id="UP000005640">
<property type="component" value="Chromosome 19"/>
</dbReference>
<dbReference type="RNAct" id="P02649">
<property type="molecule type" value="protein"/>
</dbReference>
<dbReference type="Bgee" id="ENSG00000130203">
<property type="expression patterns" value="Expressed in left adrenal gland and 235 other tissues"/>
</dbReference>
<dbReference type="ExpressionAtlas" id="P02649">
<property type="expression patterns" value="baseline and differential"/>
</dbReference>
<dbReference type="Genevisible" id="P02649">
<property type="organism ID" value="HS"/>
</dbReference>
<dbReference type="GO" id="GO:0072562">
<property type="term" value="C:blood microparticle"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042627">
<property type="term" value="C:chylomicron"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0030669">
<property type="term" value="C:clathrin-coated endocytic vesicle membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0062023">
<property type="term" value="C:collagen-containing extracellular matrix"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005737">
<property type="term" value="C:cytoplasm"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0030425">
<property type="term" value="C:dendrite"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034365">
<property type="term" value="C:discoidal high-density lipoprotein particle"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005769">
<property type="term" value="C:early endosome"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0071682">
<property type="term" value="C:endocytic vesicle lumen"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0005783">
<property type="term" value="C:endoplasmic reticulum"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="AgBase"/>
</dbReference>
<dbReference type="GO" id="GO:0005788">
<property type="term" value="C:endoplasmic reticulum lumen"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0070062">
<property type="term" value="C:extracellular exosome"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0031012">
<property type="term" value="C:extracellular matrix"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005576">
<property type="term" value="C:extracellular region"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005615">
<property type="term" value="C:extracellular space"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1903561">
<property type="term" value="C:extracellular vesicle"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0098978">
<property type="term" value="C:glutamatergic synapse"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="SynGO"/>
</dbReference>
<dbReference type="GO" id="GO:0005794">
<property type="term" value="C:Golgi apparatus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="AgBase"/>
</dbReference>
<dbReference type="GO" id="GO:0034364">
<property type="term" value="C:high-density lipoprotein particle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034363">
<property type="term" value="C:intermediate-density lipoprotein particle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1990777">
<property type="term" value="C:lipoprotein particle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034362">
<property type="term" value="C:low-density lipoprotein particle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016020">
<property type="term" value="C:membrane"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043025">
<property type="term" value="C:neuronal cell body"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005634">
<property type="term" value="C:nucleus"/>
<property type="evidence" value="ECO:0007005"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005886">
<property type="term" value="C:plasma membrane"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043083">
<property type="term" value="C:synaptic cleft"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="SynGO"/>
</dbReference>
<dbReference type="GO" id="GO:0034361">
<property type="term" value="C:very-low-density lipoprotein particle"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001540">
<property type="term" value="F:amyloid-beta binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0016209">
<property type="term" value="F:antioxidant activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0120020">
<property type="term" value="F:cholesterol transfer activity"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0043395">
<property type="term" value="F:heparan sulfate proteoglycan binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008201">
<property type="term" value="F:heparin binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042802">
<property type="term" value="F:identical protein binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0008289">
<property type="term" value="F:lipid binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0005319">
<property type="term" value="F:lipid transporter activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071813">
<property type="term" value="F:lipoprotein particle binding"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0050750">
<property type="term" value="F:low-density lipoprotein particle receptor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046911">
<property type="term" value="F:metal chelating activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0060228">
<property type="term" value="F:phosphatidylcholine-sterol O-acyltransferase activator activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005543">
<property type="term" value="F:phospholipid binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046983">
<property type="term" value="F:protein dimerization activity"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042803">
<property type="term" value="F:protein homodimerization activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0044877">
<property type="term" value="F:protein-containing complex binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005102">
<property type="term" value="F:signaling receptor binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0005198">
<property type="term" value="F:structural molecule activity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0048156">
<property type="term" value="F:tau protein binding"/>
<property type="evidence" value="ECO:0000353"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0070326">
<property type="term" value="F:very-low-density lipoprotein particle receptor binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0097113">
<property type="term" value="P:AMPA glutamate receptor clustering"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0042982">
<property type="term" value="P:amyloid precursor protein metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0048844">
<property type="term" value="P:artery morphogenesis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0006874">
<property type="term" value="P:cellular calcium ion homeostasis"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0044267">
<property type="term" value="P:cellular protein metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0019934">
<property type="term" value="P:cGMP-mediated signaling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006707">
<property type="term" value="P:cholesterol catabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0033344">
<property type="term" value="P:cholesterol efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042632">
<property type="term" value="P:cholesterol homeostasis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0008203">
<property type="term" value="P:cholesterol metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034378">
<property type="term" value="P:chylomicron assembly"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0034382">
<property type="term" value="P:chylomicron remnant clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034371">
<property type="term" value="P:chylomicron remodeling"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0007010">
<property type="term" value="P:cytoskeleton organization"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0055089">
<property type="term" value="P:fatty acid homeostasis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0007186">
<property type="term" value="P:G protein-coupled receptor signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034380">
<property type="term" value="P:high-density lipoprotein particle assembly"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034384">
<property type="term" value="P:high-density lipoprotein particle clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034375">
<property type="term" value="P:high-density lipoprotein particle remodeling"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071831">
<property type="term" value="P:intermediate-density lipoprotein particle clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0046907">
<property type="term" value="P:intracellular transport"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0010877">
<property type="term" value="P:lipid transport involved in lipid storage"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0042158">
<property type="term" value="P:lipoprotein biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042159">
<property type="term" value="P:lipoprotein catabolic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:0035641">
<property type="term" value="P:locomotory exploration behavior"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0015909">
<property type="term" value="P:long-chain fatty acid transport"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0007616">
<property type="term" value="P:long-term memory"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0034374">
<property type="term" value="P:low-density lipoprotein particle remodeling"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0051651">
<property type="term" value="P:maintenance of location in cell"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1905907">
<property type="term" value="P:negative regulation of amyloid fibril formation"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902430">
<property type="term" value="P:negative regulation of amyloid-beta formation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0030195">
<property type="term" value="P:negative regulation of blood coagulation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043537">
<property type="term" value="P:negative regulation of blood vessel endothelial cell migration"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0090090">
<property type="term" value="P:negative regulation of canonical Wnt signaling pathway"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032269">
<property type="term" value="P:negative regulation of cellular protein metabolic process"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045541">
<property type="term" value="P:negative regulation of cholesterol biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0090370">
<property type="term" value="P:negative regulation of cholesterol efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0061000">
<property type="term" value="P:negative regulation of dendritic spine development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1902951">
<property type="term" value="P:negative regulation of dendritic spine maintenance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010596">
<property type="term" value="P:negative regulation of endothelial cell migration"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0001937">
<property type="term" value="P:negative regulation of endothelial cell proliferation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0010629">
<property type="term" value="P:negative regulation of gene expression"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0050728">
<property type="term" value="P:negative regulation of inflammatory response"/>
<property type="evidence" value="ECO:0000305"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051055">
<property type="term" value="P:negative regulation of lipid biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1903001">
<property type="term" value="P:negative regulation of lipid transport across blood-brain barrier"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1900272">
<property type="term" value="P:negative regulation of long-term synaptic potentiation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043407">
<property type="term" value="P:negative regulation of MAP kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043524">
<property type="term" value="P:negative regulation of neuron apoptotic process"/>
<property type="evidence" value="ECO:0000318"/>
<property type="project" value="GO_Central"/>
</dbReference>
<dbReference type="GO" id="GO:1901215">
<property type="term" value="P:negative regulation of neuron death"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010977">
<property type="term" value="P:negative regulation of neuron projection development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1902999">
<property type="term" value="P:negative regulation of phospholipid efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010544">
<property type="term" value="P:negative regulation of platelet activation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1901627">
<property type="term" value="P:negative regulation of postsynaptic membrane organization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0050709">
<property type="term" value="P:negative regulation of protein secretion"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0090209">
<property type="term" value="P:negative regulation of triglyceride metabolic process"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0031175">
<property type="term" value="P:neuron projection development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0007263">
<property type="term" value="P:nitric oxide mediated signal transduction"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0097114">
<property type="term" value="P:NMDA glutamate receptor clustering"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0033700">
<property type="term" value="P:phospholipid efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0044794">
<property type="term" value="P:positive regulation by host of viral process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="AgBase"/>
</dbReference>
<dbReference type="GO" id="GO:1905908">
<property type="term" value="P:positive regulation of amyloid fibril formation"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1900223">
<property type="term" value="P:positive regulation of amyloid-beta clearance"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1902004">
<property type="term" value="P:positive regulation of amyloid-beta formation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010875">
<property type="term" value="P:positive regulation of cholesterol efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010873">
<property type="term" value="P:positive regulation of cholesterol esterification"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0060999">
<property type="term" value="P:positive regulation of dendritic spine development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1902952">
<property type="term" value="P:positive regulation of dendritic spine maintenance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0045807">
<property type="term" value="P:positive regulation of endocytosis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0070374">
<property type="term" value="P:positive regulation of ERK1 and ERK2 cascade"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1905855">
<property type="term" value="P:positive regulation of heparan sulfate binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1905860">
<property type="term" value="P:positive regulation of heparan sulfate proteoglycan binding"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0046889">
<property type="term" value="P:positive regulation of lipid biosynthetic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1903002">
<property type="term" value="P:positive regulation of lipid transport across blood-brain barrier"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0032805">
<property type="term" value="P:positive regulation of low-density lipoprotein particle receptor catabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051044">
<property type="term" value="P:positive regulation of membrane protein ectodomain proteolysis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1902998">
<property type="term" value="P:positive regulation of neurofibrillary tangle assembly"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1901216">
<property type="term" value="P:positive regulation of neuron death"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0010976">
<property type="term" value="P:positive regulation of neuron projection development"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0051000">
<property type="term" value="P:positive regulation of nitric-oxide synthase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1902995">
<property type="term" value="P:positive regulation of phospholipid efflux"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:1901631">
<property type="term" value="P:positive regulation of presynaptic membrane organization"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045893">
<property type="term" value="P:positive regulation of transcription, DNA-templated"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0043687">
<property type="term" value="P:post-translational protein modification"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0017038">
<property type="term" value="P:protein import"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0006898">
<property type="term" value="P:receptor-mediated endocytosis"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1905906">
<property type="term" value="P:regulation of amyloid fibril formation"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1902991">
<property type="term" value="P:regulation of amyloid precursor protein catabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:1900221">
<property type="term" value="P:regulation of amyloid-beta clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0030516">
<property type="term" value="P:regulation of axon extension"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:2000822">
<property type="term" value="P:regulation of behavioral fear response"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0032489">
<property type="term" value="P:regulation of Cdc42 protein signal transduction"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1905890">
<property type="term" value="P:regulation of cellular response to very-low-density lipoprotein particle stimulus"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0090181">
<property type="term" value="P:regulation of cholesterol metabolic process"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0045088">
<property type="term" value="P:regulation of innate immune response"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:1901214">
<property type="term" value="P:regulation of neuron death"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0048168">
<property type="term" value="P:regulation of neuronal synaptic plasticity"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0061136">
<property type="term" value="P:regulation of proteasomal protein catabolic process"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0051246">
<property type="term" value="P:regulation of protein metabolic process"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0043254">
<property type="term" value="P:regulation of protein-containing complex assembly"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:1902947">
<property type="term" value="P:regulation of tau-protein kinase activity"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="Alzheimers_University_of_Toronto"/>
</dbReference>
<dbReference type="GO" id="GO:0006357">
<property type="term" value="P:regulation of transcription by RNA polymerase II"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0061771">
<property type="term" value="P:response to caloric restriction"/>
<property type="evidence" value="ECO:0000316"/>
<property type="project" value="ARUK-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0002021">
<property type="term" value="P:response to dietary excess"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0000302">
<property type="term" value="P:response to reactive oxygen species"/>
<property type="evidence" value="ECO:0000303"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0001523">
<property type="term" value="P:retinoid metabolic process"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="Reactome"/>
</dbReference>
<dbReference type="GO" id="GO:0043691">
<property type="term" value="P:reverse cholesterol transport"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0007271">
<property type="term" value="P:synaptic transmission, cholinergic"/>
<property type="evidence" value="ECO:0000304"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0070328">
<property type="term" value="P:triglyceride homeostasis"/>
<property type="evidence" value="ECO:0000250"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0006641">
<property type="term" value="P:triglyceride metabolic process"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0071830">
<property type="term" value="P:triglyceride-rich lipoprotein particle clearance"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0042311">
<property type="term" value="P:vasodilation"/>
<property type="evidence" value="ECO:0000501"/>
<property type="project" value="Ensembl"/>
</dbReference>
<dbReference type="GO" id="GO:0034447">
<property type="term" value="P:very-low-density lipoprotein particle clearance"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="UniProtKB"/>
</dbReference>
<dbReference type="GO" id="GO:0034372">
<property type="term" value="P:very-low-density lipoprotein particle remodeling"/>
<property type="evidence" value="ECO:0000314"/>
<property type="project" value="BHF-UCL"/>
</dbReference>
<dbReference type="GO" id="GO:0019068">
<property type="term" value="P:virion assembly"/>
<property type="evidence" value="ECO:0000315"/>
<property type="project" value="AgBase"/>
</dbReference>
<dbReference type="InterPro" id="IPR000074">
<property type="entry name" value="ApoA_E"/>
</dbReference>
<dbReference type="Pfam" id="PF01442">
<property type="entry name" value="Apolipoprotein"/>
<property type="match status" value="1"/>
</dbReference>
<proteinExistence type="evidence at protein level"/>
<keyword id="KW-0002">3D-structure</keyword>
<keyword id="KW-0026">Alzheimer disease</keyword>
<keyword id="KW-1008">Amyloidosis</keyword>
<keyword id="KW-0153">Cholesterol metabolism</keyword>
<keyword id="KW-0162">Chylomicron</keyword>
<keyword id="KW-0903">Direct protein sequencing</keyword>
<keyword id="KW-0225">Disease mutation</keyword>
<keyword id="KW-0272">Extracellular matrix</keyword>
<keyword id="KW-0971">Glycation</keyword>
<keyword id="KW-0325">Glycoprotein</keyword>
<keyword id="KW-0345">HDL</keyword>
<keyword id="KW-0358">Heparin-binding</keyword>
<keyword id="KW-0380">Hyperlipidemia</keyword>
<keyword id="KW-0443">Lipid metabolism</keyword>
<keyword id="KW-0445">Lipid transport</keyword>
<keyword id="KW-0446">Lipid-binding</keyword>
<keyword id="KW-0523">Neurodegeneration</keyword>
<keyword id="KW-0558">Oxidation</keyword>
<keyword id="KW-0597">Phosphoprotein</keyword>
<keyword id="KW-0621">Polymorphism</keyword>
<keyword id="KW-1185">Reference proteome</keyword>
<keyword id="KW-0677">Repeat</keyword>
<keyword id="KW-0964">Secreted</keyword>
<keyword id="KW-0732">Signal</keyword>
<keyword id="KW-0753">Steroid metabolism</keyword>
<keyword id="KW-1207">Sterol metabolism</keyword>
<keyword id="KW-0813">Transport</keyword>
<keyword id="KW-0850">VLDL</keyword>
<feature type="signal peptide" evidence="72">
<location>
<begin position="1"/>
<end position="18"/>
</location>
</feature>
<feature type="chain" description="Apolipoprotein E" id="PRO_0000001987">
<location>
<begin position="19"/>
<end position="317"/>
</location>
</feature>
<feature type="repeat" description="1">
<location>
<begin position="80"/>
<end position="101"/>
</location>
</feature>
<feature type="repeat" description="2">
<location>
<begin position="102"/>
<end position="123"/>
</location>
</feature>
<feature type="repeat" description="3">
<location>
<begin position="124"/>
<end position="145"/>
</location>
</feature>
<feature type="repeat" description="4">
<location>
<begin position="146"/>
<end position="167"/>
</location>
</feature>
<feature type="repeat" description="5">
<location>
<begin position="168"/>
<end position="189"/>
</location>
</feature>
<feature type="repeat" description="6">
<location>
<begin position="190"/>
<end position="211"/>
</location>
</feature>
<feature type="repeat" description="7">
<location>
<begin position="212"/>
<end position="233"/>
</location>
</feature>
<feature type="repeat" description="8">
<location>
<begin position="234"/>
<end position="255"/>
</location>
</feature>
<feature type="region of interest" description="8 X 22 AA approximate tandem repeats">
<location>
<begin position="80"/>
<end position="255"/>
</location>
</feature>
<feature type="region of interest" description="LDL and other lipoprotein receptors binding" evidence="39 42">
<location>
<begin position="158"/>
<end position="168"/>
</location>
</feature>
<feature type="region of interest" description="Heparin-binding" evidence="68">
<location>
<begin position="162"/>
<end position="165"/>
</location>
</feature>
<feature type="region of interest" description="Lipid-binding and lipoprotein association" evidence="46 78">
<location>
<begin position="210"/>
<end position="290"/>
</location>
</feature>
<feature type="region of interest" description="Heparin-binding" evidence="68">
<location>
<begin position="229"/>
<end position="236"/>
</location>
</feature>
<feature type="region of interest" description="Homooligomerization" evidence="81">
<location>
<begin position="266"/>
<end position="317"/>
</location>
</feature>
<feature type="region of interest" description="Specificity for association with VLDL" evidence="78">
<location>
<begin position="278"/>
<end position="290"/>
</location>
</feature>
<feature type="modified residue" description="Methionine sulfoxide" evidence="17">
<location>
<position position="143"/>
</location>
</feature>
<feature type="modified residue" description="Phosphoserine; by FAM20C" evidence="16 56">
<location>
<position position="147"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) threonine" evidence="48">
<location>
<position position="26"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) threonine" evidence="48">
<location>
<position position="36"/>
</location>
</feature>
<feature type="glycosylation site" description="N-linked (Glc) (glycation) lysine" evidence="20">
<location>
<position position="93"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) threonine" evidence="38 53">
<location>
<position position="212"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) threonine" evidence="38">
<location>
<position position="307"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) serine" evidence="38 41">
<location>
<position position="308"/>
</location>
</feature>
<feature type="glycosylation site" description="O-linked (GalNAc...) serine" evidence="48">
<location>
<position position="314"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE5; associated with hyperlipoproteinemia and atherosclerosis; increased binding to LDL receptor; dbSNP:rs121918392." id="VAR_000645" evidence="31 59">
<original>E</original>
<variation>K</variation>
<location>
<position position="21"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE4 Philadelphia, ApoE5 French-Canadian and ApoE5-type; only ApoE4 Philadelphia is associated with HLPP3; dbSNP:rs201672011." id="VAR_000646" evidence="33 34 96">
<original>E</original>
<variation>K</variation>
<location>
<position position="31"/>
</location>
</feature>
<feature type="sequence variant" description="In LPG; ApoE2 Kyoto; dbSNP:rs121918399." id="VAR_042734" evidence="19 35">
<original>R</original>
<variation>C</variation>
<location>
<position position="43"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a patient with hypercholesterolemia; unknown pathological significance; ApoE4 Freiburg; dbSNP:rs769452." id="VAR_000647" evidence="22 57">
<original>L</original>
<variation>P</variation>
<location>
<position position="46"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE3 Freiburg; dbSNP:rs28931576." id="VAR_000648">
<original>T</original>
<variation>A</variation>
<location>
<position position="60"/>
</location>
</feature>
<feature type="sequence variant" description="Polymorphism; confirmed at protein level; dbSNP:rs370594287." id="VAR_014114" evidence="44 93">
<original>Q</original>
<variation>H</variation>
<location>
<position position="64"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE5 Frankfurt; dbSNP:rs1180612218." id="VAR_000649" evidence="79">
<original>Q</original>
<variation>K</variation>
<location>
<position position="99"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE5-type; no hyperlipidemia; dbSNP:rs11083750." id="VAR_000650" evidence="96">
<original>P</original>
<variation>R</variation>
<location>
<position position="102"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE3*; dbSNP:rs28931577." id="VAR_000651" evidence="70">
<original>A</original>
<variation>T</variation>
<location>
<position position="117"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE3 Basel; dbSNP:rs937063425." id="VAR_016789" evidence="26">
<original>A</original>
<variation>V</variation>
<location>
<position position="124"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3 and AD2; ApoE4, ApoE3 Leiden, ApoE3**, ApoE5-Frankfurt and ApoE5-type; ApoE3 Leiden and ApoE3** are associated with HLPP3; ApoE4 is associated with AD2; changed protein structure; no effect on binding to LDL receptor; decreased association with HDL and enrichment in VLDL and IDL; may prevent the interaction with MAP2 and MAPT; changed interaction with APP/A4 amyloid-beta peptide; increased ability to induce APP transcription; increased C-terminal proteolytic processing in neurons; decreased function in neurite outgrowth; dbSNP:rs429358." id="VAR_000652" evidence="21 22 25 28 46 55 61 64 75 76 78 79 80 82 83 88 90 96">
<original>C</original>
<variation>R</variation>
<location>
<position position="130"/>
</location>
</feature>
<feature type="sequence variant" description="Found in a patient with hypercholesterolemia; unknown pathological significance; ApoE1 Weisgraber; dbSNP:rs267606664." id="VAR_000653" evidence="57 80">
<original>G</original>
<variation>D</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE3 Leiden; no effect on glycosylation." id="VAR_000654" evidence="55 84">
<original>G</original>
<variation>GEVQAMLG</variation>
<location>
<position position="145"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE2-type; no hyperlipidemia; dbSNP:rs28931578." id="VAR_000655" evidence="96">
<original>R</original>
<variation>Q</variation>
<location>
<position position="152"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE2-type; dbSNP:rs121918393." id="VAR_000657" evidence="96">
<original>R</original>
<variation>C</variation>
<location>
<position position="154"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE2 Christchurch; decreased binding to LDL receptor; dbSNP:rs121918393." id="VAR_000656" evidence="45 62 80">
<original>R</original>
<variation>S</variation>
<location>
<position position="154"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE3**; dbSNP:rs387906567." id="VAR_000658" evidence="80">
<original>R</original>
<variation>C</variation>
<location>
<position position="160"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; also found in a patient with hypercholesterolemia; ApoE4 Philadelphia and ApoE2-type; dbSNP:rs769455." id="VAR_000659" evidence="22 33 57">
<original>R</original>
<variation>C</variation>
<location>
<position position="163"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; unknown pathological significance; ApoE Kochi; dbSNP:rs121918397." id="VAR_000660" evidence="43">
<original>R</original>
<variation>H</variation>
<location>
<position position="163"/>
</location>
</feature>
<feature type="sequence variant" description="In LPG; ApoE2 Sendai; decreased binding to LDL receptor; induces intraglomerular deposition of ApoE-containing lipoproteins; dbSNP:rs121918397." id="VAR_042735" evidence="21 89">
<original>R</original>
<variation>P</variation>
<location>
<position position="163"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE1 Harrisburg; decreased binding to LDL receptor; probable dominant negative effect; decreased in vitro binding to heparin; dbSNP:rs121918394." id="VAR_000662" evidence="73">
<original>K</original>
<variation>E</variation>
<location>
<position position="164"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE2**; dbSNP:rs121918394." id="VAR_000661">
<original>K</original>
<variation>Q</variation>
<location>
<position position="164"/>
</location>
</feature>
<feature type="sequence variant" description="In SBHD; also found in patients with a diagnosis of familial combined hyperlipidemia." id="VAR_035015" evidence="23 32 45 47 52 57">
<location>
<position position="167"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE3*; decreased binding to LDL receptor; dbSNP:rs267606662." id="VAR_000663" evidence="62 70">
<original>A</original>
<variation>P</variation>
<location>
<position position="170"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE2, ApoE2 Fukuoka, ApoE1 Weisgraber and ApoE3**; ApoE3** is associated with HLPP3; changed protein structure; decreased binding to LDLR and other lipoprotein receptors; decreased in vitro binding to heparin; no effect on distribution among plasma lipoproteins; dbSNP:rs7412." id="VAR_000664" evidence="22 27 28 46 67 73 77 80 87">
<original>R</original>
<variation>C</variation>
<location>
<position position="176"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE3 Washington." id="VAR_081136" evidence="29">
<location>
<begin position="228"/>
<end position="317"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE2 Fukuoka; dbSNP:rs267606663." id="VAR_000665" evidence="86">
<original>R</original>
<variation>Q</variation>
<location>
<position position="242"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE2 Dunedin; dbSNP:rs121918395." id="VAR_000666" evidence="49">
<original>R</original>
<variation>C</variation>
<location>
<position position="246"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE2 WG; dbSNP:rs199768005." id="VAR_000667" evidence="85">
<original>V</original>
<variation>E</variation>
<location>
<position position="254"/>
</location>
</feature>
<feature type="sequence variant" description="In HLPP3; ApoE7 Suita." id="VAR_000668" evidence="58">
<original>EE</original>
<variation>KK</variation>
<location>
<begin position="262"/>
<end position="263"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE3 HB; dbSNP:rs267606661." id="VAR_000669" evidence="85 90">
<original>R</original>
<variation>G</variation>
<location>
<position position="269"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE1 HE; requires 2 nucleotide substitutions." id="VAR_000670" evidence="85">
<original>L</original>
<variation>E</variation>
<location>
<position position="270"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE4 PD; dbSNP:rs121918398." id="VAR_000671" evidence="85">
<original>R</original>
<variation>H</variation>
<location>
<position position="292"/>
</location>
</feature>
<feature type="sequence variant" description="In ApoE4 HG; dbSNP:rs28931579." id="VAR_000672" evidence="85">
<original>S</original>
<variation>R</variation>
<location>
<position position="314"/>
</location>
</feature>
<feature type="mutagenesis site" description="Changes the plasma lipoprotein distribution of ApoE4 to the HDL." evidence="78">
<original>R</original>
<variation>T</variation>
<location>
<position position="79"/>
</location>
</feature>
<feature type="mutagenesis site" description="No effect on plasma lipoprotein distribution." evidence="78">
<original>E</original>
<variation>A</variation>
<location>
<position position="127"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased binding to LDL receptor; when associated with A-167." evidence="62">
<original>S</original>
<variation>R</variation>
<location>
<position position="157"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased binding to LDL receptor." evidence="62">
<original>H</original>
<variation>A</variation>
<location>
<position position="158"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased binding to LDL receptor." evidence="62">
<original>K</original>
<variation>A</variation>
<location>
<position position="161"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased binding to LDL receptor." evidence="62">
<original>L</original>
<variation>P</variation>
<location>
<position position="162"/>
</location>
</feature>
<feature type="mutagenesis site" description="Increased binding to LDL receptor; when associated with R-157." evidence="62">
<original>L</original>
<variation>A</variation>
<location>
<position position="167"/>
</location>
</feature>
<feature type="mutagenesis site" description="Decreased binding to LDL receptor." evidence="62">
<original>R</original>
<variation>A</variation>
<location>
<position position="168"/>
</location>
</feature>
<feature type="mutagenesis site" description="Restores the LDL receptor binding activity of ApoE2." evidence="87">
<original>D</original>
<variation>A</variation>
<location>
<position position="172"/>
</location>
</feature>
<feature type="mutagenesis site" description="Loss of O-glycosylation." evidence="53">
<original>T</original>
<variation>A</variation>
<location>
<position position="212"/>
</location>
</feature>
<feature type="strand" evidence="12">
<location>
<begin position="22"/>
<end position="24"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="31"/>
<end position="39"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="40"/>
<end position="42"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="43"/>
<end position="60"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="63"/>
<end position="70"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="73"/>
<end position="96"/>
</location>
</feature>
<feature type="turn" evidence="5">
<location>
<begin position="97"/>
<end position="99"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="106"/>
<end position="141"/>
</location>
</feature>
<feature type="turn" evidence="15">
<location>
<begin position="143"/>
<end position="145"/>
</location>
</feature>
<feature type="helix" evidence="3">
<location>
<begin position="149"/>
<end position="179"/>
</location>
</feature>
<feature type="turn" evidence="2">
<location>
<begin position="180"/>
<end position="182"/>
</location>
</feature>
<feature type="turn" evidence="12">
<location>
<begin position="187"/>
<end position="190"/>
</location>
</feature>
<feature type="helix" evidence="12">
<location>
<begin position="193"/>
<end position="198"/>
</location>
</feature>
<feature type="strand" evidence="14">
<location>
<begin position="200"/>
<end position="202"/>
</location>
</feature>
<feature type="helix" evidence="14">
<location>
<begin position="209"/>
<end position="217"/>
</location>
</feature>
<feature type="helix" evidence="14">
<location>
<begin position="228"/>
<end position="241"/>
</location>
</feature>
<feature type="helix" evidence="14">
<location>
<begin position="257"/>
<end position="283"/>
</location>
</feature>
<feature type="helix" evidence="9">
<location>
<begin position="286"/>
<end position="303"/>
</location>
</feature>
<feature type="strand" evidence="14">
<location>
<begin position="307"/>
<end position="309"/>
</location>
</feature>
<evidence key="1" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1B68"/>
</source>
</evidence>
<evidence key="2" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1BZ4"/>
</source>
</evidence>
<evidence key="3" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1GS9"/>
</source>
</evidence>
<evidence key="4" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1LE2"/>
</source>
</evidence>
<evidence key="5" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1LE4"/>
</source>
</evidence>
<evidence key="6" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1LPE"/>
</source>
</evidence>
<evidence key="7" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1NFN"/>
</source>
</evidence>
<evidence key="8" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1NFO"/>
</source>
</evidence>
<evidence key="9" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1OEF"/>
</source>
</evidence>
<evidence key="10" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1OR2"/>
</source>
</evidence>
<evidence key="11" type="ECO:0000244">
<source>
<dbReference type="PDB" id="1OR3"/>
</source>
</evidence>
<evidence key="12" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2KC3"/>
</source>
</evidence>
<evidence key="13" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2KNY"/>
</source>
</evidence>
<evidence key="14" type="ECO:0000244">
<source>
<dbReference type="PDB" id="2L7B"/>
</source>
</evidence>
<evidence key="15" type="ECO:0000244">
<source>
<dbReference type="PDB" id="6NCO"/>
</source>
</evidence>
<evidence key="16" type="ECO:0000244">
<source>
<dbReference type="PubMed" id="24275569"/>
</source>
</evidence>
<evidence key="17" type="ECO:0000250">
<source>
<dbReference type="UniProtKB" id="P08226"/>
</source>
</evidence>
<evidence key="18" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10027417"/>
</source>
</evidence>
<evidence key="19" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10432380"/>
</source>
</evidence>
<evidence key="20" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10452964"/>
</source>
</evidence>
<evidence key="21" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="10903326"/>
</source>
</evidence>
<evidence key="22" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11042151"/>
</source>
</evidence>
<evidence key="23" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11095479"/>
</source>
</evidence>
<evidence key="24" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11258893"/>
</source>
</evidence>
<evidence key="25" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="11447277"/>
</source>
</evidence>
<evidence key="26" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12864777"/>
</source>
</evidence>
<evidence key="27" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12950167"/>
</source>
</evidence>
<evidence key="28" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="12966036"/>
</source>
</evidence>
<evidence key="29" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1361196"/>
</source>
</evidence>
<evidence key="30" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="14754908"/>
</source>
</evidence>
<evidence key="31" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1530612"/>
</source>
</evidence>
<evidence key="32" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="16094309"/>
</source>
</evidence>
<evidence key="33" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1674745"/>
</source>
</evidence>
<evidence key="34" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1713245"/>
</source>
</evidence>
<evidence key="35" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="18077821"/>
</source>
</evidence>
<evidence key="36" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1911868"/>
</source>
</evidence>
<evidence key="37" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="1917954"/>
</source>
</evidence>
<evidence key="38" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="19838169"/>
</source>
</evidence>
<evidence key="39" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20030366"/>
</source>
</evidence>
<evidence key="40" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20303980"/>
</source>
</evidence>
<evidence key="41" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="20511397"/>
</source>
</evidence>
<evidence key="42" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2063194"/>
</source>
</evidence>
<evidence key="43" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2101409"/>
</source>
</evidence>
<evidence key="44" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22028381"/>
</source>
</evidence>
<evidence key="45" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22481068"/>
</source>
</evidence>
<evidence key="46" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2280190"/>
</source>
</evidence>
<evidence key="47" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="22949395"/>
</source>
</evidence>
<evidence key="48" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23234360"/>
</source>
</evidence>
<evidence key="49" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2341812"/>
</source>
</evidence>
<evidence key="50" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23620513"/>
</source>
</evidence>
<evidence key="51" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="23676495"/>
</source>
</evidence>
<evidence key="52" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="24267230"/>
</source>
</evidence>
<evidence key="53" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2498325"/>
</source>
</evidence>
<evidence key="54" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="25122793"/>
</source>
</evidence>
<evidence key="55" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2556398"/>
</source>
</evidence>
<evidence key="56" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26091039"/>
</source>
</evidence>
<evidence key="57" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="26802169"/>
</source>
</evidence>
<evidence key="58" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2738044"/>
</source>
</evidence>
<evidence key="59" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2760009"/>
</source>
</evidence>
<evidence key="60" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2762297"/>
</source>
</evidence>
<evidence key="61" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="28111074"/>
</source>
</evidence>
<evidence key="62" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2831187"/>
</source>
</evidence>
<evidence key="63" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="29695434"/>
</source>
</evidence>
<evidence key="64" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="2987927"/>
</source>
</evidence>
<evidence key="65" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="30448281"/>
</source>
</evidence>
<evidence key="66" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3115992"/>
</source>
</evidence>
<evidence key="67" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3243553"/>
</source>
</evidence>
<evidence key="68" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="3947350"/>
</source>
</evidence>
<evidence key="69" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="6325438"/>
</source>
</evidence>
<evidence key="70" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="6327682"/>
</source>
</evidence>
<evidence key="71" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="6860692"/>
</source>
</evidence>
<evidence key="72" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7068630"/>
</source>
</evidence>
<evidence key="73" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7635945"/>
</source>
</evidence>
<evidence key="74" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7768901"/>
</source>
</evidence>
<evidence key="75" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7891887"/>
</source>
</evidence>
<evidence key="76" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7972031"/>
</source>
</evidence>
<evidence key="77" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="7994571"/>
</source>
</evidence>
<evidence key="78" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8071364"/>
</source>
</evidence>
<evidence key="79" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8125051"/>
</source>
</evidence>
<evidence key="80" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8287539"/>
</source>
</evidence>
<evidence key="81" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8340399"/>
</source>
</evidence>
<evidence key="82" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8346443"/>
</source>
</evidence>
<evidence key="83" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8367470"/>
</source>
</evidence>
<evidence key="84" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8468528"/>
</source>
</evidence>
<evidence key="85" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8488843"/>
</source>
</evidence>
<evidence key="86" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8664327"/>
</source>
</evidence>
<evidence key="87" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8756331"/>
</source>
</evidence>
<evidence key="88" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="8939961"/>
</source>
</evidence>
<evidence key="89" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9176854"/>
</source>
</evidence>
<evidence key="90" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9360638"/>
</source>
</evidence>
<evidence key="91" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9395455"/>
</source>
</evidence>
<evidence key="92" type="ECO:0000269">
<source>
<dbReference type="PubMed" id="9488694"/>
</source>
</evidence>
<evidence key="93" type="ECO:0000269">
<source ref="10"/>
</evidence>
<evidence key="94" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="25173806"/>
</source>
</evidence>
<evidence key="95" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="29516132"/>
</source>
</evidence>
<evidence key="96" type="ECO:0000303">
<source>
<dbReference type="PubMed" id="7833947"/>
</source>
</evidence>
<evidence key="97" type="ECO:0000305"/>
<sequence length="317" mass="36154" checksum="91AFC04210A30689" modified="1986-07-21" version="1" precursor="true">MKVLWAALLVTFLAGCQAKVEQAVETEPEPELRQQTEWQSGQRWELALGRFWDYLRWVQTLSEQVQEELLSSQVTQELRALMDETMKELKAYKSELEEQLTPVAEETRARLSKELQAAQARLGADMEDVCGRLVQYRGEVQAMLGQSTEELRVRLASHLRKLRKRLLRDADDLQKRLAVYQAGAREGAERGLSAIRERLGPLVEQGRVRAATVGSLAGQPLQERAQAWGERLRARMEEMGSRTRDRLDEVKEQVAEVRAKLEEQAQQIRLQAEAFQARLKSWFEPLVEDMQRQWAGLVEKVQAAVGTSAAPVPSDNH</sequence>
</entry>
<copyright>
Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
Distributed under the Creative Commons Attribution (CC BY 4.0) License
</copyright>
</uniprot>

